
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure‐Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin‐Mediated (hATTR) Amyloidosis - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="ABCB7350925F40133D73500034745829.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="blackwellopen">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6972979/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Journal of Clinical Pharmacology">
<meta name="citation_title" content="Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure‐Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin‐Mediated (hATTR) Amyloidosis">
<meta name="citation_author" content="Xiaoping Zhang">
<meta name="citation_author_institution" content="Alnylam Pharmaceuticals, Cambridge, MA, USA">
<meta name="citation_author" content="Varun Goel">
<meta name="citation_author_institution" content="Alnylam Pharmaceuticals, Cambridge, MA, USA">
<meta name="citation_author" content="Husain Attarwala">
<meta name="citation_author_institution" content="Alnylam Pharmaceuticals, Cambridge, MA, USA">
<meta name="citation_author" content="Marianne T Sweetser">
<meta name="citation_author_institution" content="Alnylam Pharmaceuticals, Cambridge, MA, USA">
<meta name="citation_author" content="Valerie A Clausen">
<meta name="citation_author_institution" content="Alnylam Pharmaceuticals, Cambridge, MA, USA">
<meta name="citation_author" content="Gabriel J Robbie">
<meta name="citation_author_institution" content="Alnylam Pharmaceuticals, Cambridge, MA, USA">
<meta name="citation_publication_date" content="2019 Jul 19">
<meta name="citation_volume" content="60">
<meta name="citation_issue" content="1">
<meta name="citation_firstpage" content="37">
<meta name="citation_doi" content="10.1002/jcph.1480">
<meta name="citation_pmid" content="31322739">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC6972979/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC6972979/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC6972979/pdf/JCPH-60-37.pdf">
<meta name="description" content="Hereditary transthyretin‐mediated (hATTR) amyloidosis is an inherited, rapidly progressive, life‐threatening disease caused by deposition of abnormal transthyretin protein. Patisiran is an RNA interference therapeutic comprising a novel, small ...">
<meta name="og:title" content="Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure‐Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin‐Mediated (hATTR) Amyloidosis">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Hereditary transthyretin‐mediated (hATTR) amyloidosis is an inherited, rapidly progressive, life‐threatening disease caused by deposition of abnormal transthyretin protein. Patisiran is an RNA interference therapeutic comprising a novel, small ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC6972979/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="6972979">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1002/jcph.1480"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/JCPH-60-37.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC6972979%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/6972979/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/6972979/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC6972979/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-blackwellopen.png" alt="Wiley Open Access Collection logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Wiley Open Access Collection" title="Link to Wiley Open Access Collection" shape="default" href="https://doi.org/10.1002/jcph.1480" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">J Clin Pharmacol</button></div>. 2019 Jul 19;60(1):37–49. doi: <a href="https://doi.org/10.1002/jcph.1480" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1002/jcph.1480</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22J%20Clin%20Pharmacol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22J%20Clin%20Pharmacol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J%20Clin%20Pharmacol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22J%20Clin%20Pharmacol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure‐Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin‐Mediated (hATTR) Amyloidosis</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Xiaoping Zhang</span></a><div hidden="hidden" id="id1">
<h3>
<span class="name western">Xiaoping Zhang</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup><sup>1</sup></sup>Alnylam Pharmaceuticals, Cambridge, MA, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xiaoping Zhang</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Goel%20V%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Varun Goel</span></a><div hidden="hidden" id="id2">
<h3>
<span class="name western">Varun Goel</span>, <span class="degrees">PhD</span>
</h3>
<div class="p">
<sup><sup>1</sup></sup>Alnylam Pharmaceuticals, Cambridge, MA, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Goel%20V%22%5BAuthor%5D" class="usa-link"><span class="name western">Varun Goel</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Attarwala%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Husain Attarwala</span></a><div hidden="hidden" id="id3">
<h3>
<span class="name western">Husain Attarwala</span>, <span class="degrees">PhD</span>
</h3>
<div class="p">
<sup><sup>1</sup></sup>Alnylam Pharmaceuticals, Cambridge, MA, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Attarwala%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Husain Attarwala</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sweetser%20MT%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Marianne T Sweetser</span></a><div hidden="hidden" id="id4">
<h3>
<span class="name western">Marianne T Sweetser</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup><sup>1</sup></sup>Alnylam Pharmaceuticals, Cambridge, MA, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sweetser%20MT%22%5BAuthor%5D" class="usa-link"><span class="name western">Marianne T Sweetser</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Clausen%20VA%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Valerie A Clausen</span></a><div hidden="hidden" id="id5">
<h3>
<span class="name western">Valerie A Clausen</span>, <span class="degrees">PhD</span>
</h3>
<div class="p">
<sup><sup>1</sup></sup>Alnylam Pharmaceuticals, Cambridge, MA, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Clausen%20VA%22%5BAuthor%5D" class="usa-link"><span class="name western">Valerie A Clausen</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Robbie%20GJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Gabriel J Robbie</span></a><div hidden="hidden" id="id6">
<h3>
<span class="name western">Gabriel J Robbie</span>, <span class="degrees">PhD</span>
</h3>
<div class="p">
<sup><sup>1</sup></sup>Alnylam Pharmaceuticals, Cambridge, MA, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Robbie%20GJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Gabriel J Robbie</span></a>
</div>
</div>
<sup>1</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="jcph1480-aff-0001">
<sup><sup>1</sup></sup>Alnylam Pharmaceuticals, Cambridge, MA, USA</div>
<div class="author-notes p">
<div class="fn" id="correspondenceTo">
<sup>*</sup><p class="display-inline"><strong>Corresponding Author</strong>: Xiaoping Zhang, MD, PhD, Department of Clinical Pharmacology, Alnylam Pharmaceuticals Inc., 300 Third Street, Cambridge, MA 02142, Email: <span>x.amy.zhang@gmail.com</span></p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2019 Feb 25; Accepted 2019 Jun 12; Issue date 2020 Jan.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2019 The Authors. <em>The Journal of Clinical Pharmacology</em> published by Wiley Periodicals, Inc. on behalf of American College of Clinical Pharmacology</div>
<p>This is an open access article under the terms of the <a href="http://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC6972979  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31322739/" class="usa-link">31322739</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>Hereditary transthyretin‐mediated (hATTR) amyloidosis is an inherited, rapidly progressive, life‐threatening disease caused by deposition of abnormal transthyretin protein. Patisiran is an RNA interference therapeutic comprising a novel, small interfering ribonucleic acid (ALN‐18328) formulated in a lipid nanoparticle targeted to inhibit hepatic transthyretin protein synthesis. The lipid nanoparticle also contains 2 novel lipid excipients (DLin‐MC3‐DMA and PEG<sub>2000</sub>‐C‐DMG). Here we report patisiran pharmacokinetics (PK), pharmacodynamics (PD), and exposure‐response analyses from the phase 3 APOLLO trial, in which patients with hATTR amyloidosis with polyneuropathy were randomized 2:1 to receive patisiran 0.3 mg/kg or placebo intravenously every 3 weeks over 18 months. In patisiran‐treated patients, mean maximum reduction in serum transthyretin level from baseline was 87.8%. Patisiran PK exposure was stable following chronic dosing. There were no meaningful differences in PK exposure, serum transthyretin reduction, and efficacy (change from baseline in modified Neuropathy Impairment Score+7) across all subgroups analyzed (age, sex, race, body weight, genotype status of valine‐to‐methionine mutation at position 30 [V30M] and non‐V30M, prior use of tetramer stabilizers, mild/moderate renal impairment, and mild hepatic impairment). transthyretin reduction and efficacy were similar across the interpatient PK exposure range for ALN‐18328. There was no trend in the incidence of adverse events or serious adverse events across the interpatient PK exposure range for all 3 analytes. Incidence of antidrug antibodies was low (3.4%) and transient, with no impact on PK, PD, efficacy, or safety. The patisiran dosing regimen of 0.3 mg/kg every 3 weeks is appropriate for all patients with hATTR amyloidosis.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> exposure‐response, hereditary transthyretin‐mediated amyloidosis (hATTR), patisiran, pharmacodynamics (PD), pharmacokinetics (PK), small interfering ribonucleic acid (siRNA)</p></section></section><hr class="headless">
<p>Hereditary transthyretin‐mediated (hATTR) amyloidosis is an inherited, multisystem, rapidly progressive, and often fatal disease caused by mutations in the transthyretin gene.<a href="#jcph1480-bib-0001" class="usa-link" aria-describedby="jcph1480-bib-0001">1</a>, <a href="#jcph1480-bib-0002" class="usa-link" aria-describedby="jcph1480-bib-0002">2</a> The transthyretin protein is primarily produced in the liver<a href="#jcph1480-bib-0003" class="usa-link" aria-describedby="jcph1480-bib-0003">3</a> and forms a tetramer that transports vitamin A (retinol) in association with retinol‐binding protein (RBP) in the plasma and cerebrospinal fluid.<a href="#jcph1480-bib-0004" class="usa-link" aria-describedby="jcph1480-bib-0004">4</a>, <a href="#jcph1480-bib-0005" class="usa-link" aria-describedby="jcph1480-bib-0005">5</a> To date, more than 120 <em>transthyretin</em> mutations have been identified,<a href="#jcph1480-bib-0006" class="usa-link" aria-describedby="jcph1480-bib-0006">6</a> of which the most common is the valine‐to‐methionine mutation at position 30 (V30M).<a href="#jcph1480-bib-0007" class="usa-link" aria-describedby="jcph1480-bib-0007">7</a> These pathogenic transthyretin mutations result in misfolded transthyretin proteins that accumulate as amyloid deposits at multiple sites including peripheral nerves, heart, kidney, and gastrointestinal tract.<a href="#jcph1480-bib-0001" class="usa-link" aria-describedby="jcph1480-bib-0001">1</a>, <a href="#jcph1480-bib-0008" class="usa-link" aria-describedby="jcph1480-bib-0008">8</a> This gives rise to a heterogeneous clinical presentation including sensory, motor, and autonomic polyneuropathy and cardiomyopathy, as well as other disease manifestations.<a href="#jcph1480-bib-0001" class="usa-link" aria-describedby="jcph1480-bib-0001">1</a>, <a href="#jcph1480-bib-0002" class="usa-link" aria-describedby="jcph1480-bib-0002">2</a>, <a href="#jcph1480-bib-0009" class="usa-link" aria-describedby="jcph1480-bib-0009">9</a>, <a href="#jcph1480-bib-0010" class="usa-link" aria-describedby="jcph1480-bib-0010">10</a>, <a href="#jcph1480-bib-0011" class="usa-link" aria-describedby="jcph1480-bib-0011">11</a> The disease has a rapid progression, with a median survival of 4.7 years following diagnosis, reduced to 3.4 years for patients presenting with cardiomyopathy.<a href="#jcph1480-bib-0012" class="usa-link" aria-describedby="jcph1480-bib-0012">12</a>, <a href="#jcph1480-bib-0013" class="usa-link" aria-describedby="jcph1480-bib-0013">13</a>, <a href="#jcph1480-bib-0014" class="usa-link" aria-describedby="jcph1480-bib-0014">14</a>, <a href="#jcph1480-bib-0015" class="usa-link" aria-describedby="jcph1480-bib-0015">15</a>
</p>
<p>Therapeutic treatment options for hATTR amyloidosis include transthyretin tetramer stabilizers (tafamidis and diflunisal), transthyretin‐reduction pharmacotherapies (patisiran and inotersen), and surgical intervention (orthotopic liver transplant).<a href="#jcph1480-bib-0001" class="usa-link" aria-describedby="jcph1480-bib-0001">1</a>, <a href="#jcph1480-bib-0016" class="usa-link" aria-describedby="jcph1480-bib-0016">16</a>, <a href="#jcph1480-bib-0017" class="usa-link" aria-describedby="jcph1480-bib-0017">17</a> Patisiran is a first‐in‐class RNA interference (RNAi) therapeutic recently approved in the United States and Europe to treat the polyneuropathy caused by hATTR amyloidosis.<a href="#jcph1480-bib-0018" class="usa-link" aria-describedby="jcph1480-bib-0018">18</a>, <a href="#jcph1480-bib-0019" class="usa-link" aria-describedby="jcph1480-bib-0019">19</a>, <a href="#jcph1480-bib-0020" class="usa-link" aria-describedby="jcph1480-bib-0020">20</a> The recommended dose of patisiran is 0.3 mg/kg administered via intravenous infusion every 3 weeks, with a maximum dose of 30 mg for patients weighing ≥100 kg. The patisiran drug substance is a novel small interfering RNA (siRNA) formulated as a lipid nanoparticle.<a href="#jcph1480-bib-0021" class="usa-link" aria-describedby="jcph1480-bib-0021">21</a> lipid nanoparticle technology is used as a delivery system for RNAi therapeutics and gene therapy<a href="#jcph1480-bib-0022" class="usa-link" aria-describedby="jcph1480-bib-0022">22</a>, <a href="#jcph1480-bib-0023" class="usa-link" aria-describedby="jcph1480-bib-0023">23</a> to protect therapeutic oligonucleotides from degradation by endogenous enzymes in biological fluids<a href="#jcph1480-bib-0024" class="usa-link" aria-describedby="jcph1480-bib-0024">24</a> and to facilitate targeted siRNA delivery into hepatocytes.<a href="#jcph1480-bib-0021" class="usa-link" aria-describedby="jcph1480-bib-0021">21</a>, <a href="#jcph1480-bib-0022" class="usa-link" aria-describedby="jcph1480-bib-0022">22</a>, <a href="#jcph1480-bib-0023" class="usa-link" aria-describedby="jcph1480-bib-0023">23</a> The structure of an RNAi therapeutic lipid nanoparticle consists of a largely hydrophobic core with inverted micelles of lipid that encapsulate the siRNA drug substance, which is surrounded by a roughly homogeneous outer coating of polyethylene glycol (PEG) lipids.<a href="#jcph1480-bib-0023" class="usa-link" aria-describedby="jcph1480-bib-0023">23</a>, <a href="#jcph1480-bib-0025" class="usa-link" aria-describedby="jcph1480-bib-0025">25</a> In patisiran, the lipid nanoparticle is composed of the siRNA (ALN‐18328) and 4 lipid excipients, 2 of which have been used in marketed drugs (DSPC [1,2 distearoyl‐sn‐glycero‐3‐phosphocholine] and cholesterol)<a href="#jcph1480-bib-0023" class="usa-link" aria-describedby="jcph1480-bib-0023">23</a> and 2 novel lipids, which are being used as excipients for the first time (DLin‐MC3‐DMA [(6Z, 9Z, 28Z, 31Z)‐heptatriaconta‐6, 9, 28, 31‐tetraen‐19‐yl‐4‐(dimethylamino) butanoate] and PEG<sub>2000</sub>‐C‐DMG (α‐(3′‐{[1,2‐di(myristyloxy)proponoxy]carbonylamino}propyl)‐ω‐methoxy, polyoxyethylene). PEG<sub>2000</sub>‐C‐DMG aids lipid nanoparticle stability in circulation after intravenous administration and provides optimum circulation time, thereby enabling uptake of patisiran into the liver, the primary site of transthyretin synthesis.<a href="#jcph1480-bib-0021" class="usa-link" aria-describedby="jcph1480-bib-0021">21</a>, <a href="#jcph1480-bib-0022" class="usa-link" aria-describedby="jcph1480-bib-0022">22</a>, <a href="#jcph1480-bib-0023" class="usa-link" aria-describedby="jcph1480-bib-0023">23</a> DLin‐MC3‐DMA is important for particle formation, fusogenicity, cellular uptake, and endosomal release of the siRNA into the cell's cytoplasm.<a href="#jcph1480-bib-0023" class="usa-link" aria-describedby="jcph1480-bib-0023">23</a>, <a href="#jcph1480-bib-0025" class="usa-link" aria-describedby="jcph1480-bib-0025">25</a> In addition, DSPC and cholesterol provide physicochemical stability to the lipid nanoparticle.<a href="#jcph1480-bib-0023" class="usa-link" aria-describedby="jcph1480-bib-0023">23</a> The lipid nanoparticle facilitates siRNA delivery into hepatocytes through apolipoprotein E uptake, mediated by low‐density lipoprotein receptors, following which the lipid nanoparticle structure is perturbed, resulting in release of ALN‐18328 into the cytoplasm.<a href="#jcph1480-bib-0021" class="usa-link" aria-describedby="jcph1480-bib-0021">21</a>, <a href="#jcph1480-bib-0023" class="usa-link" aria-describedby="jcph1480-bib-0023">23</a> There, ALN‐18328 binds to the RNA‐induced silencing complex, resulting in the targeted degradation of wild‐type and mutant <em>transthyretin</em> messenger RNA and subsequent reduction of transthyretin synthesis.<a href="#jcph1480-bib-0026" class="usa-link" aria-describedby="jcph1480-bib-0026">26</a>, <a href="#jcph1480-bib-0027" class="usa-link" aria-describedby="jcph1480-bib-0027">27</a>
</p>
<p>The clinical development program for patisiran comprised 6 clinical studies.<a href="#jcph1480-bib-0028" class="usa-link" aria-describedby="jcph1480-bib-0028">28</a> In the phase 1 and 2 studies, ALN‐18328 plasma exposure increased in an approximately dose‐proportional manner over the dose range of 0.01 to 0.5 mg/kg, resulting in rapid and dose‐dependent reduction of serum transthyretin levels.<a href="#jcph1480-bib-0021" class="usa-link" aria-describedby="jcph1480-bib-0021">21</a>, <a href="#jcph1480-bib-0029" class="usa-link" aria-describedby="jcph1480-bib-0029">29</a> Based on phase 1 and 2 studies, patisiran 0.3 mg/kg once every 3 weeks was selected for evaluation in patients with hATTR amyloidosis with polyneuropathy in the subsequent pivotal APOLLO trial.</p>
<p>Efficacy and safety results from the APOLLO trial have been reported elsewhere.<a href="#jcph1480-bib-0017" class="usa-link" aria-describedby="jcph1480-bib-0017">17</a> Patisiran significantly improved polyneuropathy, quality of life, gait speed, activities of daily living, and nutritional status in patients with hATTR amyloidosis.<a href="#jcph1480-bib-0017" class="usa-link" aria-describedby="jcph1480-bib-0017">17</a>
</p>
<p>Here we report pharmacokinetics (PK), pharmacodynamics (PD), and antidrug antibody (ADA) results from the APOLLO trial. The objectives of the present analyses were to evaluate (1) plasma PK of ALN‐18328 and the 2 novel lipid excipients (DLin‐MC3‐DMA and PEG<sub>2000</sub>‐C‐DMG); (2) PD effects on serum levels of transthyretin, vitamin A, and RBP; (3) the effect of intrinsic and extrinsic factors on PK, PD, and efficacy; (4) the effect of PK exposure on transthyretin reduction, efficacy, and safety; (5) the incidence and titer of ADAs; and (6) the effect of ADAs on PK exposure, transthyretin reduction, efficacy, and safety.</p>
<section id="jcph1480-sec-0020"><h2 class="pmc_sec_title">Methods</h2>
<section id="jcph1480-sec-0030"><h3 class="pmc_sec_title">Study Design</h3>
<p>The APOLLO study methods have been described in detail previously<a href="#jcph1480-bib-0017" class="usa-link" aria-describedby="jcph1480-bib-0017">17</a>, <a href="#jcph1480-bib-0030" class="usa-link" aria-describedby="jcph1480-bib-0030">30</a> and are briefly summarized here. APOLLO was a randomized, multicenter, double‐blind, placebo‐controlled phase 3 study in adult patients with hATTR amyloidosis with polyneuropathy (<a href="https://clinicaltrials.gov/ct2/show/NCT01960348" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01960348</a>). The study was conducted at 44 sites worldwide,<a href="#jcph1480-bib-0017" class="usa-link" aria-describedby="jcph1480-bib-0017">17</a> and was performed in accordance with the principles associated with the World Health Organization Declaration of Helsinki and the Health Insurance Portability and Accountability Act of 1996. The study protocol was approved by the local or central institutional review boards and ethics committees for each study site. Written informed consent was obtained from all participating patients before any study‐related procedures were performed.</p>
<p>Patients were randomized 2:1 to receive patisiran 0.3 mg/kg or placebo intravenously every 3 weeks for 18 months. The maximum dose of patisiran was 31.2 mg for patients who weighed 104 kg or more. All patients received premedications to minimize the risk of infusion‐related reactions. In addition, patients received a daily oral vitamin A supplement containing the recommended daily allowance. The primary end point was change from baseline in modified Neuropathy Impairment Score+7 (mNIS+7)<a href="#jcph1480-bib-0031" class="usa-link" aria-describedby="jcph1480-bib-0031">31</a> at 18 months. Safety assessments included adverse‐event (AE) monitoring and clinical laboratory safety tests throughout the study. AEs and serious AEs (SAEs) were coded according to the Medical Dictionary for Regulatory Activities (version 18.0).</p></section><section id="jcph1480-sec-0040"><h3 class="pmc_sec_title">Pharmacokinetic Assessments</h3>
<p>In the APOLLO trial, a sparse PK sample strategy was implemented, as previous phase 1 and 2 trials had investigated PK properties with intensive PK sampling.<a href="#jcph1480-bib-0021" class="usa-link" aria-describedby="jcph1480-bib-0021">21</a>, <a href="#jcph1480-bib-0029" class="usa-link" aria-describedby="jcph1480-bib-0029">29</a>, <a href="#jcph1480-bib-0032" class="usa-link" aria-describedby="jcph1480-bib-0032">32</a> Blood samples for plasma PK analysis were taken at the following times over the 18‐month treatment period: predose in weeks 0, 3, 18, 36, 57, and 78 (C<sub>min</sub> predose plasma concentration [C<sub>min</sub>]); at the end of infusion in weeks 0, 18, and 57 (maximum postinfusion plasma concentration [C<sub>max</sub>]); and 30 minutes after the end of infusion in weeks 3, 36, and 78 (concentration 30 minutes postinfusion [C<sub>p(30min)</sub>]).</p>
<p>Plasma concentrations of ALN‐18328 were measured with a validated ATTO probe assay using a high‐performance liquid chromatography (HPLC)/fluorescence detection method with a lower limit of quantification (LLOQ) of 1 ng/mL.<a href="#jcph1480-bib-0021" class="usa-link" aria-describedby="jcph1480-bib-0021">21</a> Precision was ≤9.1% (% coefficient of variation [CV%]) and accuracy ranged from −2.7% to 2.5% (% difference between found and nominal concentration). Plasma concentrations of DLin‐MC3‐DMA and PEG<sub>2000</sub>‐C‐DMG were measured using 2 validated liquid chromatography with tandem mass spectrometry methods with LLOQ of 0.5 and 5.0 ng/mL, respectively. For the DLin‐MC3‐DMA high‐range assay (LLOQ, 5 ng/mL), precision was ≤13.4%, and accuracy ranged from 0.6% to 6.7%. For the DLin‐MC3‐DMA low‐range assay (LLOQ, 0.5 ng/mL), precision was ≤9.7%, and accuracy ranged from −2.5% to 0.3%. For the PEG<sub>2000</sub>‐C‐DMG assay, precision was ≤7.4%, and accuracy ranged from −1.3% to 1.4%.</p></section><section id="jcph1480-sec-0050"><h3 class="pmc_sec_title">Pharmacodynamic Assessments</h3>
<p>Blood samples for PD analysis (serum transthyretin, vitamin A, and RBP levels) were collected: predose in weeks 0, 3, 15, 36, 39, 57, and 78, 2‐7 days postdose in weeks 37‐38 (month 9) and weeks 79‐80 (month 18), and in week 81, 3 weeks after the last dose. Blood samples were obtained before vitamin A supplementation.</p>
<p>Total serum transthyretin was quantified using a custom‐developed, validated, sandwich enzyme‐linked immunosorbent assay (ELISA; LLOQ, 1.13 ng/mL).<a href="#jcph1480-bib-0040" class="usa-link" aria-describedby="jcph1480-bib-0040">33</a> Serum vitamin A and RBP were analyzed by commercial in vitro diagnostic methods: vitamin A using an HPLC method (Chromsystems Instruments and Chemicals GmBH, Munich, Germany) and RBP using immunonephelometry (Siemens, Erlangen, Germany).</p></section><section id="jcph1480-sec-0060"><h3 class="pmc_sec_title">ADA Assessments</h3>
<p>Blood samples to evaluate ADA status in serum were collected at predose in weeks 0, 3, 18, 36, 57, and 78. A validated ELISA method that specifically detected antibodies to PEG<sub>2000</sub>‐C‐DMG on the lipid nanoparticle was used for the screening and confirmatory ADA assays. PEG<sub>2000</sub>‐C‐DMG was coated onto the plate, and captured ADAs were detected using antihuman immunoglobulin G/immunoglobulin M antibodies. Serum samples were first analyzed with a screening assay. Samples testing positive for ADAs in the screening assay were further evaluated in a confirmatory assay. For the samples that tested positive for ADA in the confirmatory assay, ADA titer was then determined as the reciprocal of the highest dilution of the sample that yielded a positive ADA test result.</p></section><section id="jcph1480-sec-0070"><h3 class="pmc_sec_title">Analysis Population</h3>
<p>The PD population was defined as all patients who were randomized and received at least 1 dose of patisiran or placebo. The PK population was defined as all patisiran‐treated patients with ≥1 PK concentration measurement. The PK/PD population was defined as all patients who had both PK and PD data.</p></section><section id="jcph1480-sec-0080"><h3 class="pmc_sec_title">Statistical Methods</h3>
<p>Plasma concentrations of ALN‐18328 and DLin‐MC3‐DMA reached steady state (ss) after 24 weeks of treatment in the phase 2 open‐label extension study.<a href="#jcph1480-bib-0032" class="usa-link" aria-describedby="jcph1480-bib-0032">32</a> Hence, in the APOLLO trial, steady state PK parameters were calculated by averaging concentrations obtained after 24 weeks as follows: C<sub>min,ss</sub> in weeks 36, 57, and 78, C<sub>p,ss(30 min)</sub> in weeks 36 and 78, and C<sub>max,ss</sub> in week 57. Descriptive summary statistics were obtained for all PK parameters. Plasma concentrations below the LLOQ were treated as zero. Previous analysis of phase 2 studies demonstrated that plasma concentrations (C<sub>min</sub>, C<sub>max</sub>, and C<sub>p(30 min)</sub>) were linearly correlated with overall PK exposure (area under the plasma concentration‐time curve during a dosing interval, AUC<sub>τ</sub>) after the first dose<a href="#jcph1480-bib-0029" class="usa-link" aria-describedby="jcph1480-bib-0029">29</a> and at steady state<a href="#jcph1480-bib-0032" class="usa-link" aria-describedby="jcph1480-bib-0032">32</a> (Pearson correlation R = 0.668 to 0.794 and <em>P</em> &lt; 0.001; data on file). Therefore, in the present analysis these PK concentration parameters at steady state (C<sub>min,ss</sub>, C<sub>p,ss(30 min)</sub>, and C<sub>max,ss</sub>) were used as surrogates of AUC<sub>τ</sub> for PK subgroup analyses and PK exposure‐response analyses.</p>
<p>Descriptive statistics for mean percent reduction from baseline for PD parameters were derived by (1) study visit, (2) averaging individual patient reductions using all postbaseline measurements over 18 months of treatment, and (3) averaging individual patient maximum reductions observed during the study. Baseline was defined as the average value for all PD measurements before the first dose at screening and on day 1. For PD subgroup analysis, mean reduction from baseline using all postbaseline measurements was used.</p>
<p>PK parameters, transthyretin change from baseline, and efficacy (difference between patisiran and placebo groups in mNIS+7 change from baseline at 18 months) were summarized across the following subgroups of intrinsic and extrinsic factors: sex (male vs female), age (&lt;65 vs ≥65 years), V30M genotype status (yes vs no), race (white vs nonwhite), body weight (&lt;100 vs ≥100 kg), prior use of transthyretin tetramer stabilizers (yes vs no), ADA status (positive vs negative), renal function (normal vs mild vs moderate impairment), and hepatic function (normal vs mild impairment). Renal impairment subgroups were defined based on estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease equation<a href="#jcph1480-bib-0033" class="usa-link" aria-describedby="jcph1480-bib-0033">34</a>; eGFR ≥90 mL/min/1.73 m<sup>2</sup> indicated normal renal function, eGFR ≥ 60‐&lt;90 mL/min/1.73 m<sup>2</sup> indicated mild renal impairment, and eGFR ≥30–&lt;60 mL/min/1.73 m<sup>2</sup> indicated moderate renal impairment. Hepatic impairment subgroups were defined by National Cancer Institute Organ Dysfunction Working Group criteria.<a href="#jcph1480-bib-0034" class="usa-link" aria-describedby="jcph1480-bib-0034">35</a> These criteria are based on serum aspartate transaminase (AST) and bilirubin (BIL) values<a href="#jcph1480-bib-0034" class="usa-link" aria-describedby="jcph1480-bib-0034">35</a>: BIL ≤ upper limit of normal (ULN) and AST ≤ ULN indicated normal hepatic function (BIL ≤ ULN and AST &gt; ULN) or ULN &lt; BIL ≤ 1.5 × ULN indicated mild hepatic impairment, and 1.5 × ULN &lt; BIL ≤ 3 × ULN indicated moderate hepatic impairment.</p>
<p>For subgroup comparisons, the following statistical tests were performed<a href="#jcph1480-bib-0035" class="usa-link" aria-describedby="jcph1480-bib-0035">36</a>: for normally distributed variables, the 2‐sample <em>t</em> test and analysis of variance were used to evaluate group differences for subgroups with 2 levels and more than 2 levels, respectively; for variables that were not normally distributed, the Wilcoxon rank sum test and Kruskal‐Wallis test were used to evaluate group differences for subgroups with 2 levels and more than 2 levels, respectively. All tests were 2‐sided at the .05 significance level. Type I error was controlled using a false discovery rate procedure that accounted for the correlated nature of the hypothesis tests, and adjusted <em>P</em> values are presented.<a href="#jcph1480-bib-0036" class="usa-link" aria-describedby="jcph1480-bib-0036">37</a>, <a href="#jcph1480-bib-0037" class="usa-link" aria-describedby="jcph1480-bib-0037">38</a>
</p>
<p>To evaluate the impact of interpatient variability in PK on transthyretin reduction, clinical efficacy, and safety, PK exposure parameters from the PK/PD population were divided into 4 quartiles (≤25%, &gt;25%‐≤50%, &gt;50%‐≤75%, and &gt;75%‐≤100%). Serum transthyretin reduction from baseline over 18 months and change from baseline in mNIS+7 at 18 months versus placebo were summarized in each ALN‐18328 PK exposure quartile. Similar analyses were performed for the lipid excipients (DLin‐MC3‐DMA and PEG<sub>2000</sub>‐C‐DMG). Incidence of treatment‐emergent AEs and SAEs, which were related or possibly related to study drug as determined by investigators, were summarized in each PK exposure quartile for ALN‐18328 and the lipid excipients (DLin‐MC3‐DMA and PEG<sub>2000</sub>‐C‐DMG).</p>
<p>PK and statistical analysis were performed using Phoenix WinNonlin software version 7.0 (Certara USA, Inc., Princeton, New Jersey) and SAS software version 9.4 (SAS Institute Inc., Cary, North Carolina), respectively. Graphical analysis was performed using Microsoft Office 365 (Microsoft Corporation, Redmond, Washington) and R version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria).<a href="#jcph1480-bib-0038" class="usa-link" aria-describedby="jcph1480-bib-0038">39</a>
</p></section></section><section id="jcph1480-sec-0090"><h2 class="pmc_sec_title">Results</h2>
<section id="jcph1480-sec-0100"><h3 class="pmc_sec_title">Patient Demographics and Baseline Characteristics</h3>
<p>Baseline demographics and disease characteristics have been previously published<a href="#jcph1480-bib-0017" class="usa-link" aria-describedby="jcph1480-bib-0017">17</a>; additional patient characteristics are shown in Table <a href="#jcph1480-tbl-0001" class="usa-link">1</a>. A total of 225 patients were randomly assigned in a 2:1 ratio to receive patisiran (n = 148) or placebo (n = 77). At baseline, mNIS+7 and serum levels of transthyretin, vitamin A, and RBP were similar in the 2 treatment groups (Table <a href="#jcph1480-tbl-0001" class="usa-link">1</a>). All 225 patients were included in the PD analysis. The PK and PK/PD populations comprised 147 patients randomized to patisiran, as 1 patient received a partial dose in the first infusion and withdrew from the study shortly after it began.<a href="#jcph1480-bib-0017" class="usa-link" aria-describedby="jcph1480-bib-0017">17</a>
</p>
<section class="tw xbox font-sm" id="jcph1480-tbl-0001" lang="en"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Baseline Demographic and Clinical Characteristics</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead><tr style="border-bottom:solid 1px #000000" valign="bottom">
<th align="left" valign="bottom" rowspan="1" colspan="1">Characteristic<a href="#jcph1480-tbl1-note-0002" class="usa-link"><sup>a</sup></a>
</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Placebo (n = 77)</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Patisiran 0.3 mg/kg Once Every 3 Weeks (n = 148)</th>
</tr></thead>
<tbody>
<tr><td colspan="3" align="left" rowspan="1">Age category, n (%)</td></tr>
<tr>
<td style="padding-left:10%" align="left" rowspan="1" colspan="1">&lt;65 years</td>
<td align="center" rowspan="1" colspan="1">44 (57.1)</td>
<td align="center" rowspan="1" colspan="1">86 (58.1)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" rowspan="1" colspan="1">≥65 years</td>
<td align="center" rowspan="1" colspan="1">33 (42.9)</td>
<td align="center" rowspan="1" colspan="1">62 (41.9)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Body weight, kg</td>
<td align="center" rowspan="1" colspan="1">67.5 ± 15.7 (40.8‐99.0)</td>
<td align="center" rowspan="1" colspan="1">67.3 ± 16.6 (36.2‐110.0)</td>
</tr>
<tr><td colspan="3" align="left" rowspan="1">Body weight category, n (%)</td></tr>
<tr>
<td style="padding-left:10%" align="left" rowspan="1" colspan="1">&lt;100 kg</td>
<td align="center" rowspan="1" colspan="1">77 (100.0)</td>
<td align="center" rowspan="1" colspan="1">141 (95.3)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" rowspan="1" colspan="1">≥100 kg</td>
<td align="center" rowspan="1" colspan="1">0 (0.0)</td>
<td align="center" rowspan="1" colspan="1">7 (4.7)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">mNIS+7</td>
<td align="center" rowspan="1" colspan="1">74.6 ± 37.0 (11.0‐154.0)</td>
<td align="center" rowspan="1" colspan="1">80.9 ± 41.5 (8.0‐165.0)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">TTR, mg/L</td>
<td align="center" rowspan="1" colspan="1">199 ± 58.1 (59.0‐320.0)</td>
<td align="center" rowspan="1" colspan="1">197 ± 67.7 (52.0‐411.0)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Vitamin A, µg/dL</td>
<td align="center" rowspan="1" colspan="1">37.0 ± 12.3 (14.0‐67.0)</td>
<td align="center" rowspan="1" colspan="1">37.8 ± 13.7 (11.0‐70.0)<a href="#jcph1480-tbl1-note-0003" class="usa-link"><sup>b</sup></a>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">RBP, mg/dL</td>
<td align="center" rowspan="1" colspan="1">3.85 ± 1.41 (1.7‐7.2)</td>
<td align="center" rowspan="1" colspan="1">3.89 ± 1.55 (1.7‐8.0)</td>
</tr>
<tr><td colspan="3" align="left" rowspan="1">Hepatic function, n (%)</td></tr>
<tr>
<td style="padding-left:10%" align="left" rowspan="1" colspan="1">Normal</td>
<td align="center" rowspan="1" colspan="1">75 (97.4)</td>
<td align="center" rowspan="1" colspan="1">138 (93.2)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" rowspan="1" colspan="1">Mild impairment</td>
<td align="center" rowspan="1" colspan="1">2 (2.6)</td>
<td align="center" rowspan="1" colspan="1">10 (6.8)</td>
</tr>
<tr><td colspan="3" align="left" rowspan="1">Renal function, n (%)</td></tr>
<tr>
<td style="padding-left:10%" align="left" rowspan="1" colspan="1">Normal</td>
<td align="center" rowspan="1" colspan="1">49 (63.6)</td>
<td align="center" rowspan="1" colspan="1">104 (70.3)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" rowspan="1" colspan="1">Mild impairment</td>
<td align="center" rowspan="1" colspan="1">23 (29.9)</td>
<td align="center" rowspan="1" colspan="1">28 (18.9)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" rowspan="1" colspan="1">Moderate impairment</td>
<td align="center" rowspan="1" colspan="1">5 (6.5)</td>
<td align="center" rowspan="1" colspan="1">16 (10.8)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/jcph1480-tbl-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="jcph1480-tbl1-note-0001"><p>mNIS+7, modified Neuropathy Impairment Score+7; RBP, retinol‐binding protein; TTR, transthyretin.</p></div>
<div class="fn" id="jcph1480-tbl1-note-0002">
<sup>a</sup><p class="display-inline">Data are presented from baseline study visits and expressed as mean ± standard deviation (range) except where specified otherwise.</p>
</div>
<div class="fn" id="jcph1480-tbl1-note-0003">
<sup>b</sup><p class="display-inline">n = 147.</p>
</div>
</div></section><p>In the 148 patients in the patisiran group, mean body weight was 67.3 kg, and 7 patients (4.73%) weighed ≥100 kg; there were more male than female patients (109 vs 39), and the majority of patients (113 of 148 [76.4%]) were white.<a href="#jcph1480-bib-0017" class="usa-link" aria-describedby="jcph1480-bib-0017">17</a> Ten patients (6.76%) treated with patisiran had mild hepatic impairment, 28 (18.9%) had mild renal impairment, and 16 (10.8%) had moderate renal impairment. A total of 56 patients (37.8%) in the patisiran group had the V30M genotype, and 78 (52.7%) had received prior transthyretin tetramer stabilizer treatment.<a href="#jcph1480-bib-0017" class="usa-link" aria-describedby="jcph1480-bib-0017">17</a>
</p></section><section id="jcph1480-sec-0110"><h3 class="pmc_sec_title">PK</h3>
<p>Sparse plasma concentrations of ALN‐18328, DLin‐MC3‐DMA, and PEG<sub>2000</sub>‐C‐DMG over 18 months are shown in Figure <a href="#jcph1480-fig-0001" class="usa-link">1</a>. PK parameters for ALN‐18328, DLin‐MC3‐DMA, and PEG<sub>2000</sub>‐C‐DMG after the first dose and at steady state are summarized in Table <a href="#jcph1480-tbl-0002" class="usa-link">2</a>.</p>
<figure class="fig xbox font-sm" id="jcph1480-fig-0001" lang="en"><h4 class="obj_head">Figure 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/6972979/2ea366af6b12/JCPH-60-37-g001.jpg" loading="lazy" id="nlm-graphic-1" height="787" width="380" alt="Figure 1"></p>
<div class="p text-right font-secondary"><a href="figure/jcph1480-fig-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Mean plasma concentrations of (A) ALN‐18328, (B) DLin‐MC3‐DMA, and (C) PEG<sub>2000</sub>‐C‐DMG (semilog scale) after administration of patisiran 0.3 mg/kg once every 3 weeks over 18 months in patients (PK population). The error bars represent the ± standard deviation. Note: 1‐sided error bars for ALN‐18328 and some PEG<sub>2000</sub>‐C‐DMG concentrations are presented because values are negative. ALN‐18328, patisiran drug substance (small interfering RNA); C<sub>max</sub>, maximum concentration observed at end of infusion; C<sub>p(30 minutes)</sub>, concentration observed 30 minutes postinfusion; C<sub>min</sub>, observed predose concentration; DLin‐MC3‐DMA, lipid excipient (6Z,9Z,28Z,31Z)‐heptatriaconta‐6,9,28,31‐tetraen‐19‐yl‐4‐(dimethylamino) butanoate; PEG<sub>2000</sub>‐C‐DMG, lipid excipient α‐(3′‐{[1,2‐di(myristyloxy)proponoxy]carbonylamino}propyl)‐ω‐methoxy, polyoxyethylene; PK, pharmacokinetic.</p></figcaption></figure><section class="tw xbox font-sm" id="jcph1480-tbl-0002" lang="en"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Summary of PK Parameters for ALN‐18328, DLin‐MC3‐DMA, and PEG<sub>2000</sub>‐C‐DMG After Intravenous Administration of Patisiran 0.3 mg/kg Once Every 3 Weeks</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead><tr style="border-bottom:solid 1px #000000">
<th align="left" rowspan="1" colspan="1">PK Parameter<a href="#jcph1480-tbl2-note-0002" class="usa-link"><sup>a</sup></a>
</th>
<th align="center" rowspan="1" colspan="1">n</th>
<th align="center" rowspan="1" colspan="1">ALN‐18328</th>
<th align="center" rowspan="1" colspan="1">n</th>
<th align="center" rowspan="1" colspan="1">DLin‐MC3‐DMA</th>
<th align="center" rowspan="1" colspan="1">n</th>
<th align="center" rowspan="1" colspan="1">PEG<sub>2000</sub>‐C‐DMG</th>
</tr></thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">C<sub>max,1</sub>, µg/mL</td>
<td align="center" rowspan="1" colspan="1">141</td>
<td align="center" rowspan="1" colspan="1">5.51 ± 2.32 (42.1%)</td>
<td align="center" rowspan="1" colspan="1">141</td>
<td align="center" rowspan="1" colspan="1">35.6 ± 12.8 (35.8%)</td>
<td align="center" rowspan="1" colspan="1">142</td>
<td align="center" rowspan="1" colspan="1">3.75 ± 1.15 (30.6%)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">C<sub>max,ss</sub>, µg/mL</td>
<td align="center" rowspan="1" colspan="1">135</td>
<td align="center" rowspan="1" colspan="1">6.48 ± 2.22 (34.3%)</td>
<td align="center" rowspan="1" colspan="1">135</td>
<td align="center" rowspan="1" colspan="1">36.9 ± 11.7 (31.6%)</td>
<td align="center" rowspan="1" colspan="1">135</td>
<td align="center" rowspan="1" colspan="1">4.07 ± 1.08 (26.5%)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">R<sub>ac</sub> for C<sub>max,ss</sub>
</td>
<td align="center" rowspan="1" colspan="1"></td>
<td align="center" rowspan="1" colspan="1">1.18</td>
<td align="center" rowspan="1" colspan="1"></td>
<td align="center" rowspan="1" colspan="1">1.04</td>
<td align="center" rowspan="1" colspan="1"></td>
<td align="center" rowspan="1" colspan="1">1.09</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">C<sub>p,2(30 min)</sub>, µg/mL</td>
<td align="center" rowspan="1" colspan="1">139</td>
<td align="center" rowspan="1" colspan="1">4.02 ± 2.12 (52.9%)</td>
<td align="center" rowspan="1" colspan="1">139</td>
<td align="center" rowspan="1" colspan="1">25.6 ± 12.0 (46.9%)</td>
<td align="center" rowspan="1" colspan="1">140</td>
<td align="center" rowspan="1" colspan="1">3.08 ± 1.18 (38.3%)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">C<sub>p,ss(30 min)</sub>, µg/mL</td>
<td align="center" rowspan="1" colspan="1">141</td>
<td align="center" rowspan="1" colspan="1">4.97 ± 1.59 (32.0%)</td>
<td align="center" rowspan="1" colspan="1">141</td>
<td align="center" rowspan="1" colspan="1">30.9 ± 9.46 (30.6%)</td>
<td align="center" rowspan="1" colspan="1">141</td>
<td align="center" rowspan="1" colspan="1">3.64 ± 0.92 (25.3%)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">R<sub>ac</sub> for C<sub>p,ss(30 min)</sub>
</td>
<td align="center" rowspan="1" colspan="1">—</td>
<td align="center" rowspan="1" colspan="1">1.24</td>
<td align="center" rowspan="1" colspan="1">—</td>
<td align="center" rowspan="1" colspan="1">1.21</td>
<td align="center" rowspan="1" colspan="1">—</td>
<td align="center" rowspan="1" colspan="1">1.18</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">C<sub>min,1</sub>,<a href="#jcph1480-tbl2-note-0003" class="usa-link"><sup>b</sup></a> µg/mL</td>
<td align="center" rowspan="1" colspan="1">139</td>
<td align="center" rowspan="1" colspan="1">0.010 ± 0.047 (470%)</td>
<td align="center" rowspan="1" colspan="1">138</td>
<td align="center" rowspan="1" colspan="1">0.365 ± 0.350 (95.9%)</td>
<td align="center" rowspan="1" colspan="1">140</td>
<td align="center" rowspan="1" colspan="1">0.0244 ± 0.0373 (153%)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">C<sub>min,ss</sub>,<a href="#jcph1480-tbl2-note-0004" class="usa-link"><sup>c</sup></a> µg/mL</td>
<td align="center" rowspan="1" colspan="1">141</td>
<td align="center" rowspan="1" colspan="1">0.0241 ± 0.132 (547%)</td>
<td align="center" rowspan="1" colspan="1">141</td>
<td align="center" rowspan="1" colspan="1">1.37 ± 0.456 (33.2%)</td>
<td align="center" rowspan="1" colspan="1">141</td>
<td align="center" rowspan="1" colspan="1">0.030 ± 0.013 (43.2%)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">R<sub>ac</sub> for C<sub>min,ss</sub>
</td>
<td align="center" rowspan="1" colspan="1">—</td>
<td align="center" rowspan="1" colspan="1">2.41</td>
<td align="center" rowspan="1" colspan="1">—</td>
<td align="center" rowspan="1" colspan="1">3.75</td>
<td align="center" rowspan="1" colspan="1">—</td>
<td align="center" rowspan="1" colspan="1">1.23</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/jcph1480-tbl-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="jcph1480-tbl2-note-0001"><p>ALN‐18328, patisiran drug substance (small interfering RNA); C<sub>max,1</sub>, maximum concentration observed at end of infusion after first dose on day 1; C<sub>max,ss</sub>, maximum concentration observed at end of infusion at steady state; C<sub>p,2(30 min)</sub>, concentration observed 30 minutes postinfusion after second dose on day 21; C<sub>p,ss(30 min)</sub>, concentration observed 30 minutes postinfusion at steady state; C<sub>min,1</sub>, predose concentration observed at the end of first dosing interval and before the second dose; C<sub>min,ss</sub>, predose concentration observed at steady state; PK, pharmacokinetics; R<sub>ac</sub>, accumulation ratio (PK exposure at steady state: first dose); DLin‐MC3‐DMA, (6Z,9Z,28Z,31Z)‐heptatriaconta‐6,9,28,31‐tetraen‐19‐yl‐4 (dimethylamino) butanoate; PEG<sub>2000</sub>‐C‐DMG, α‐(3′‐{[1,2‐di(myristyloxy)propanoxy]carbonylamino}propyl)‐ω‐methoxy, polyoxyethylene; n, sample size.</p></div>
<div class="fn" id="jcph1480-tbl2-note-0002">
<sup>a</sup><p class="display-inline">Data are expressed as mean ± standard deviation (% coefficient of variation).</p>
</div>
<div class="fn" id="jcph1480-tbl2-note-0003">
<sup>b</sup><p class="display-inline">34.5% of C<sub>min,1</sub> values were below the lower limit of quantification and treated as zero.</p>
</div>
<div class="fn" id="jcph1480-tbl2-note-0004">
<sup>c</sup><p class="display-inline">17.2% of C<sub>min,ss</sub> values were below the lower limit of quantification and treated as zero.</p>
</div>
</div></section><p>For ALN‐18328 and DLin‐MC3‐DMA, plasma C<sub>min</sub> increased slightly from the first dose to 18 weeks and was stable thereafter, whereas plasma C<sub>max</sub> and C<sub>p(30min)</sub> were similar across all measured times from the first dose to the last dose (Figure <a href="#jcph1480-fig-0001" class="usa-link">1</a>A,B, respectively, Table <a href="#jcph1480-tbl-0002" class="usa-link">2</a>). At steady state, mean C<sub>max,ss</sub>, C<sub>p,ss(30 min)</sub>, and C<sub>min,ss</sub> were 6.48, 4.97, and 0.0241 µg/mL for ALN‐18328, respectively, and 36.9, 30.9, and 1.37 µg/mL for DLin‐MC3‐DMA, respectively (Table <a href="#jcph1480-tbl-0002" class="usa-link">2</a>). For PEG<sub>2000</sub>‐C‐DMG, no appreciable increases in plasma C<sub>max</sub>, C<sub>p(30 min)</sub>, and C<sub>min</sub> were observed during the 18‐month treatment period (Figure <a href="#jcph1480-fig-0001" class="usa-link">1</a>C, Table <a href="#jcph1480-tbl-0002" class="usa-link">2</a>). Interpatient PK variability, as measured by CV%, was low to moderate, ranging from 25.3% to 43.2% for ALN‐18328 (C<sub>max,ss</sub> and C<sub>p,ss(30 min)</sub>), DLin‐MC3‐DMA, and PEG<sub>2000</sub>‐C‐DMG (C<sub>max,ss</sub>, C<sub>p,ss(30 min)</sub>, and C<sub>min,ss</sub>); see Table <a href="#jcph1480-tbl-0002" class="usa-link">2</a>. However, a significant number of ALN‐18328 C<sub>min,ss</sub> values were below the LLOQ, resulting in a large interpatient variability of 547%.</p>
<p>The ALN‐18328 PK parameters (C<sub>max,ss</sub>, C<sub>p,ss(30 min)</sub>, and C<sub>min,ss</sub>) did not show statistically significant differences across the following subgroups studied: age, sex, body weight, race, V30M genotype, renal function (normal, mild, and moderate impairment), hepatic function (normal and mild impairment), and prior use of transthyretin tetramer stabilizers (Figure <a href="#jcph1480-fig-0002" class="usa-link">2</a>). The mean ± SD C<sub>max,ss</sub> of ALN‐18328 in patients with mild hepatic impairment (4.63 ± 1.14 µg/mL) was numerically lower than that in patients with normal hepatic function (6.57 ± 2.23 µg/mL), but this difference was not statistically significant after controlling for type I error (<em>P</em> = .2208). Similar findings were shown for PK parameters of the 2 lipid excipients, DLin‐MC3‐DMA and PEG<sub>2000</sub>‐C‐DMG (<a href="#jcph1480-supl-0001" class="usa-link">Supplementary Table S1)</a>.</p>
<figure class="fig xbox font-sm" id="jcph1480-fig-0002" lang="en"><h4 class="obj_head">Figure 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/6972979/e814b8f6cf64/JCPH-60-37-g002.jpg" loading="lazy" id="nlm-graphic-3" height="1001" width="350" alt="Figure 2"></p>
<div class="p text-right font-secondary"><a href="figure/jcph1480-fig-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Mean steady‐state plasma concentrations of ALN‐18328 across patient subgroups. (A) C<sub>max,ss</sub>, (B) C<sub>p,ss(30 min)</sub>, and (C) C<sub>min,ss</sub>. The error bars represent the standard deviation. There were no statistically significant differences within subgroups after controlling for type I error. ALN‐18328, patisiran drug substance (small interfering RNA); BW, body weight; C<sub>max,ss</sub>, maximum concentration observed at end of infusion at steady state; C<sub>p,ss(30 min)</sub>, concentration observed 30 minutes postinfusion at steady state; C<sub>min,ss</sub>, predose concentration observed at steady state; HF, hepatic function; HI, hepatic impairment; RI, renal impairment; RF, renal function; TTR, transthyretin.</p></figcaption></figure><p>Across a wide range of body weights, from 36.2 to 110 kg, higher ALN‐18328 PK exposure (C<sub>max,ss</sub> and C<sub>p,ss(30min)</sub>) was seen with increasing body weight (Figure <a href="#jcph1480-fig-0003" class="usa-link">3</a>A, <a href="#jcph1480-supl-0001" class="usa-link">Supplementary Table S2</a>). The PK exposures increased by 1.3‐ to 1.5‐fold from body‐weight quartile 1 (range, 36.2‐56.6 kg) to quartile 4 (range, 79.5‐110 kg). A similar trend of higher PK exposure (C<sub>max,ss</sub> and C<sub>p,ss(30min)</sub>) with increasing body weight was seen with the 2 lipid excipients (DLin‐MC3‐DMA and PEG<sub>2000</sub>‐C‐DMG) across the 4 body‐weight quartiles (<a href="#jcph1480-supl-0001" class="usa-link">Supplementary Figure S1</a>, <a href="#jcph1480-supl-0001" class="usa-link">Supplementary Table S2</a>).</p>
<figure class="fig xbox font-sm" id="jcph1480-fig-0003" lang="en"><h4 class="obj_head">Figure 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/6972979/153bbeafe52a/JCPH-60-37-g003.jpg" loading="lazy" id="nlm-graphic-5" height="646" width="600" alt="Figure 3"></p>
<div class="p text-right font-secondary"><a href="figure/jcph1480-fig-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Effect of body weight on ALN‐18328 PK exposure and TTR reduction. Box plots by body‐weight quartiles for (A) C<sub>max,ss</sub> and C<sub>p,ss(30min)</sub> for ALN‐18328 and (B) individual maximum TTR reduction and individual mean TTR reduction over 18 months. The lower and upper bounds of the rectangles represent the first and third quartiles, the horizontal line represents the median, the whiskers extend to the highest and lowest values within 1.5 × the the interquartile range, and data beyond the end of the whiskers are plotted as points. Body weights associated with the 4 quartiles are: Q1, 36.2‐56.6 kg; Q2, 56.9‐65.0 kg; Q3, 66.0‐79.0 kg; and Q4, 79.5‐110 kg. ALN‐18328, patisiran drug substance (small interfering RNA); C<sub>max,ss</sub>, maximum concentration observed at end of infusion at steady state; C<sub>p,ss(30 min)</sub>, concentration observed 30 minutes postinfusion at steady state; PK, pharmacokinetic; TTR, transthyretin.</p></figcaption></figure></section><section id="jcph1480-sec-0120"><h3 class="pmc_sec_title">Pharmacodynamics</h3>
<p>In the patisiran treatment group, serum transthyretin reduction was rapid and sustained over the 18‐month duration of the study,<a href="#jcph1480-bib-0017" class="usa-link" aria-describedby="jcph1480-bib-0017">17</a> with a mean reduction of 82.6% and 84.3% at 9 and 18 months, respectively. The mean maximum serum transthyretin reduction was 87.8%. As expected, following patisiran treatment,<a href="#jcph1480-bib-0004" class="usa-link" aria-describedby="jcph1480-bib-0004">4</a>, <a href="#jcph1480-bib-0005" class="usa-link" aria-describedby="jcph1480-bib-0005">5</a> serum vitamin A and RBP levels also decreased in parallel with decreasing serum transthyretin levels, with mean reductions over 18 months of 62.4% for vitamin A and 45.3% for RBP. In the placebo group, there was no appreciable change in serum transthyretin levels over the 18‐month duration of the study.<a href="#jcph1480-bib-0017" class="usa-link" aria-describedby="jcph1480-bib-0017">17</a> As expected, there were also no appreciable changes in vitamin A or RBP levels over 18 months of placebo treatment (Figure <a href="#jcph1480-fig-0004" class="usa-link">4</a>A,B, respectively). Furthermore, scatter plots showed that changes in vitamin A (<em>R</em>
<sup>2</sup> = 0.777; <em>P</em> &lt; .001) and RBP (<em>R</em>
<sup>2</sup> = 0.515; <em>P</em> &lt; .001) were linearly correlated with changes in transthyretin (data not shown).</p>
<figure class="fig xbox font-sm" id="jcph1480-fig-0004" lang="en"><h4 class="obj_head">Figure 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/6972979/34884019314f/JCPH-60-37-g004.jpg" loading="lazy" id="nlm-graphic-7" height="486" width="400" alt="Figure 4"></p>
<div class="p text-right font-secondary"><a href="figure/jcph1480-fig-0004/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Mean change from baseline over time for serum levels of (A) vitamin A and (B) retinol‐binding protein in the patisiran and placebo groups (PD population). The error bars represent the standard error of the mean. PD, pharmacodynamic.</p></figcaption></figure><p>There was no difference in mean or mean maximum serum transthyretin reduction from baseline over the 18‐month duration of the study across the 4 body‐weight quartiles (Figure <a href="#jcph1480-fig-0003" class="usa-link">3</a>B, <a href="#jcph1480-supl-0001" class="usa-link">Supplementary Table S2</a>).</p></section><section id="jcph1480-sec-0130"><h3 class="pmc_sec_title">Subgroup Analysis of Efficacy and Transthyretin</h3>
<p>In the patisiran group, mean serum transthyretin reduction from baseline over 18 months’ treatment was not statistically significantly different across all subgroups analyzed (Figure <a href="#jcph1480-fig-0005" class="usa-link">5</a>A), ranging from 71.4% to 82%. The mean ± SD serum transthyretin reduction in patients with mild hepatic impairment (71.4% ± 12.6%) was numerically lower than in patients with normal hepatic function (78.0% ± 16.5%). However, the difference was not statistically significant (<em>P</em> = .631). A slightly higher mean ± SD percent reduction in transthyretin was seen in patients with prior use of tetramer stabilizers (82.0% ± 7.84%) compared with patients without prior use of tetramer stabilizers (72.8% ± 21.3%; <em>P</em> = .0054). However, the mean ± SD serum transthyretin level over 18 months of treatment was comparable in the 2 groups of patients (38.5 ± 24.6 vs 44.1 ± 43.0 µg/mL).</p>
<figure class="fig xbox font-sm" id="jcph1480-fig-0005" lang="en"><h4 class="obj_head">Figure 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/6972979/c106e89bdce7/JCPH-60-37-g005.jpg" loading="lazy" id="nlm-graphic-9" height="387" width="780" alt="Figure 5"></p>
<div class="p text-right font-secondary"><a href="figure/jcph1480-fig-0005/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Analysis by intrinsic and extrinsic factors for change from baseline to 18 months with ALN‐18328 in (A) mean serum TTR levels compared with baseline and (B) mean mNIS+7 from baseline at 18 months compared with placebo. The error bars represent the standard error of the mean. <sup>a</sup>Data from Adams et al 2018.<a href="#jcph1480-bib-0017" class="usa-link" aria-describedby="jcph1480-bib-0017">17</a> BW, body weight; HF, hepatic function; HI, hepatic impairment; mNIS+7, modified Neuropathy Impairment Score+7; RF, renal function; RI, renal impairment; TTR, transthyretin.</p></figcaption></figure><p>The mean mNIS+7 change from baseline compared with placebo was also similar across all subgroups analyzed (Figure <a href="#jcph1480-fig-0005" class="usa-link">5</a>B), ranging from −28.3 to −37.3 points.</p></section><section id="jcph1480-sec-0140"><h3 class="pmc_sec_title">Effect of Interpatient PK Variability on transthyretin and Efficacy</h3>
<p>In the patisiran group, the mean reduction in serum transthyretin from baseline over 18 months of treatment was similar across the 4 PK exposure quartiles for all 3 PK parameters with ALN‐18328 (Figure <a href="#jcph1480-fig-0006" class="usa-link">6</a>A), ranging from 71% to 81%. Similar results were seen for the 2 lipid excipients: mean transthyretin reduction from baseline ranged from 75.2% to 80.5% for DLin‐MC3‐DMA and from 74.6% to 80.3% for PEG<sub>2000</sub>‐C‐DMG across the 4 PK exposure quartiles for all 3 PK exposure parameters analyzed (data not shown).</p>
<figure class="fig xbox font-sm" id="jcph1480-fig-0006" lang="en"><h4 class="obj_head">Figure 6.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/6972979/515909dc8e67/JCPH-60-37-g006.jpg" loading="lazy" id="nlm-graphic-11" height="189" width="600" alt="Figure 6"></p>
<div class="p text-right font-secondary"><a href="figure/jcph1480-fig-0006/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Effect of interpatient PK variability on (A) TTR change from baseline and (B) mNIS+7 change from baseline compared with placebo (PK/PD population). Quartile 1, 0%‐≤25%; quartile 2, &gt;25%‐≤50%; quartile 3, &gt;50%‐≤75%; quartile 4, &gt;75%‐≤100%. The error bars represent the standard error of the mean. ALN‐18328, patisiran drug substance (small interfering RNA); C<sub>max,ss</sub>, maximum concentration observed at end of infusion at steady state; C<sub>p,ss(30 min)</sub>, concentration observed 30 minutes postinfusion at steady state; C<sub>min,ss</sub>, predose concentration observed at steady state; mNIS+7, modified Neuropathy Impairment Score+7; PD, pharmacodynamic; PK, pharmacokinetic; TTR, transthyretin.</p></figcaption></figure><p>The mean change in mNIS+7 from baseline to 18 months compared with placebo was comparable across the 4 PK exposure quartiles for all 3 PK parameters with ALN‐18328 (Figure <a href="#jcph1480-fig-0006" class="usa-link">6</a>B), ranging from −26.9 to −37.4 points. Similar mean changes in mNIS+7 from baseline to 18 months compared with placebo were noted for the 2 lipid excipients, ranging from −28.08 to −34.85 points for DLin‐MC3‐DMA and from −27.98 to −36.08 points for PEG<sub>2000</sub>‐C‐DMG across the 4 PK exposure quartiles (data not shown).</p></section><section id="jcph1480-sec-0150"><h3 class="pmc_sec_title">Effect of Interpatient PK Variability on Safety</h3>
<p>Primary safety results from the APOLLO trial have been reported previously.<a href="#jcph1480-bib-0017" class="usa-link" aria-describedby="jcph1480-bib-0017">17</a> Here we examined the effect of interpatient variability in PK on the incidence of treatment‐emergent AEs and SAEs. The incidence of AEs or SAEs was similar across the 4 PK exposure quartiles for all 3 PK parameters for ALN‐18328, DLin‐MC3‐DMA, and PEG<sub>2000</sub>‐C‐DMG (<a href="#jcph1480-supl-0001" class="usa-link">Supplementary Table S3</a>).</p></section><section id="jcph1480-sec-0160"><h3 class="pmc_sec_title">Immunogenicity</h3>
<p>Two of 224 patients (0.89%) tested positive for ADAs at baseline: 1 in the patisiran group and 1 in the placebo group. The overall incidence of treatment‐emergent ADAs was 3.4% (5 of 145 patients) in the patisiran group and 1.3% (1 of 77 patients) in the placebo group. The 5 patisiran‐treated patients tested positive for ADAs in week 3, with 2 patients also testing positive in week 18, but ADA positivity was transient, as all samples tested negative at subsequent visits through to end of the study. ADA titer ranged from 40 to 160.</p>
<p>Plasma PK exposures (C<sub>max,ss</sub>, C<sub>p,ss(30 min)</sub>, and C<sub>min,ss</sub>) for ALN‐18328, DLin‐MC3‐DMA, and PEG<sub>2000</sub>‐C‐DMG were comparable in the ADA‐positive and ADA‐negative groups (<a href="#jcph1480-supl-0001" class="usa-link">Supplementary Table S4</a>). The mean reduction from baseline in serum transthyretin levels over 18 months of treatment was similar in ADA‐positive patients (n = 5 in week 3; n = 2 in week 18; range, 69%‐79%) and ADA‐negative patients (n = 134 to n = 138 from weeks 3 to 78; range, 73%‐77%). The mean ± standard error of the mean difference between patisiran and placebo treatment in mNIS+7 change from baseline was also similar in ADA‐positive (n = 6; −30.8 ± 9.46) and ADA‐negative (n = 131; −32.2 ± 3.21) groups at 18 months. In the patisiran group, the patients with positive ADA status at any time postbaseline (n = 6) displayed a pattern of AEs and SAEs similar to that observed in the overall safety population.</p></section></section><section id="jcph1480-sec-0170"><h2 class="pmc_sec_title">Discussion</h2>
<p>The present analyses of PK and PD data from the APOLLO study demonstrated that chronic dosing of patisiran 0.3 mg/kg every 3 weeks resulted in stable plasma concentrations of ALN‐18328 and the 2 novel lipid excipients (DLin‐MC3‐DMA and PEG<sub>2000</sub>‐C‐DMG) over 18 months of treatment. This dosing regimen elicited a rapid, robust, and sustained reduction in serum levels of the transthyretin protein. Subgroup analysis demonstrated that intrinsic and extrinsic factors had no meaningful impact on plasma PK exposures for all 3 analytes, serum transthyretin reduction, or clinical efficacy. Furthermore, interpatient variability in PK exposure for all 3 analytes did not result in differences in transthyretin reduction, clinical efficacy, or safety (AEs or SAEs).</p>
<p>ALN‐18328 is a synthetic double‐stranded oligonucleotide that is metabolized by nucleases to nucleotides of various lengths.<a href="#jcph1480-bib-0018" class="usa-link" aria-describedby="jcph1480-bib-0018">18</a> Nucleases belong to the hydrolase class of enzymes, which exist ubiquitously in the body and are not expected to be significantly different in patients with mild hepatic impairment. Hence, it is not surprising to see no effect of mild hepatic impairment on plasma ALN‐18328 PK exposure. In addition, mechanisms of siRNA delivery to hepatocytes and RNAi‐mediated suppression of transthyretin protein in the liver<a href="#jcph1480-bib-0021" class="usa-link" aria-describedby="jcph1480-bib-0021">21</a> were also not impacted, as similar transthyretin reduction from baseline was observed for patients with mild hepatic impairment versus those with normal hepatic function.</p>
<p>In previous studies, it was determined that negligible amounts of ALN‐18328 (&lt;1% of the dose) were excreted in the urine following patisiran dosing,<a href="#jcph1480-bib-0018" class="usa-link" aria-describedby="jcph1480-bib-0018">18</a> indicating that ALN‐18328 is not renally cleared. Therefore, the lack of effect of mild and moderate renal impairment on ALN‐18328 PK exposure is also as expected.</p>
<p>The similar ALN‐18328 PK exposures and transthyretin reductions seen in V30M and non‐V30M genotype patients in the present analysis are consistent with the observation in the APOLLO study that change in mNIS+7 with patisiran was not affected by transthyretin genotype (V30M and non‐V30M).<a href="#jcph1480-bib-0017" class="usa-link" aria-describedby="jcph1480-bib-0017">17</a> The similar results across different transthyretin mutations are expected because siRNA (ALN‐18328) was designed to bind to a genetically conserved sequence in the 3′ untranslated region of transthyretin mRNA and thus mediate degradation of both wild‐type and mutant transthyretin mRNA regardless of the specific pathogenic mutation.<a href="#jcph1480-bib-0021" class="usa-link" aria-describedby="jcph1480-bib-0021">21</a>
</p>
<p>Patients with prior use of transthyretin stabilizers had higher baseline transthyretin levels in the present study compared with patients without prior use of transthyretin stabilizers. This is consistent with the finding in patients with transthyretin amyloid cardiomyopathy treated with an investigational transthyretin stabilizer (AG10) in which transthyretin levels were restored to the normal range.<a href="#jcph1480-bib-0039" class="usa-link" aria-describedby="jcph1480-bib-0039">40</a> The similar absolute serum transthyretin levels seen in patients with and without prior use of tetramer stabilizers over 18 months with patisiran treatment indicates similar PD effect of patisiran across these patients. The greater percentage reduction from baseline in patients with prior use of tetramer stabilizers is likely an artifact of higher baseline consequent to an inadequate washout period (≤14 days) in some patients prior to the start of patisiran dosing in the APOLLO trial. This was supported by higher mean ± SD baseline values in the patients with prior use of transthyretin stabilizers compared with those with no prior use (222 ± 65 vs 169 ± 59 µg/mL).</p>
<p>A clear trend toward higher PK exposures of ALN‐18328 and the 2 lipid excipients was seen with increasing body weight (range, 36.2‐110 kg). This can be attributed to the higher absolute dose that is administered to heavier patients. Despite the slight differences in PK exposure with body weight, observed serum transthyretin reductions were similar across the body‐weight range studied. This is because the therapeutic dose of patisiran (0.3 mg/kg every 3 weeks) yields ALN‐18328 concentrations that are in the plateau portion of the concentration‐effect curve, resulting in 80% to 90% reduction in serum transthyretin,<a href="#jcph1480-bib-0040" class="usa-link" aria-describedby="jcph1480-bib-0040">33</a> where slight changes in PK concentrations do not result in meaningful differences in PD response.</p>
<p>A maximum absolute patisiran dose of 30 mg is proposed for patients weighing &gt;100 kg, which results in a body‐weight adjusted dose that is slightly lower than 0.3 mg/kg. The ALN‐18328 plasma concentrations arising from the absolute dose of 30 mg given to patients weighing &gt;100 kg are expected to be in the plateau portion of the concentration‐effect curve, resulting in similar transthyretin lowering and mNIS+7 change as in patients weighing ≤100 kg receiving patisiran 0.3 mg/kg. This was indeed seen in the 7 patients who weighed &gt;100 kg, in whom ALN‐18328 PK exposure was about 35%‐40% higher, yet serum transthyretin reduction and mNIS+7 change were similar to patients weighing ≤100 kg.</p>
<p>Exposure to ALN‐18328 and serum transthyretin reduction was observed to be numerically lower in patients with mild hepatic impairment than in patients with normal hepatic function, although these differences were not statistically significant. Of the patients with mild hepatic impairment who provided data, 4 of 6 C<sub>max,ss</sub> values and 6 of 8 C<sub>p,ss(30min)</sub> values were in the first quartile range of body weight. This suggests that the lower PK exposure observed in patients with mild hepatic impairment compared with patients with normal hepatic function was likely a result of low body weight.</p>
<p>Interpatient variability in ALN‐18328 PK exposure with patisiran 0.3 mg/kg every‐3‐week dosing in the APOLLO trial did not lead to differences in serum transthyretin reductions from baseline and clinical efficacy, confirming that 0.3 mg/kg every 3 weeks results in plasma concentrations in the plateau phase of the patisiran dose‐response curve for transthyretin reduction, as reported in the phase 1 and 2 trials.<a href="#jcph1480-bib-0021" class="usa-link" aria-describedby="jcph1480-bib-0021">21</a>, <a href="#jcph1480-bib-0029" class="usa-link" aria-describedby="jcph1480-bib-0029">29</a>, <a href="#jcph1480-bib-0040" class="usa-link" aria-describedby="jcph1480-bib-0040">33</a> Comparable serum transthyretin reductions from baseline were also observed across the PK exposure range of DLin‐MC3‐DMA and PEG<sub>2000</sub>‐C‐DMG, confirming that interpatient variability in the PK of the 2 lipid excipients had no impact on the magnitude of transthyretin reduction. In addition, similar transthyretin reduction across 4 PK exposure quartiles of the 2 lipid excipients was an indirect indicator that the amount of siRNA (ALN‐18328) that was delivered to the hepatocytes was not impacted by interpatient variability in the PK of the lipid excipients.</p>
<p>Population PK<a href="#jcph1480-bib-0040" class="usa-link" aria-describedby="jcph1480-bib-0040">33</a>, <a href="#jcph1480-bib-0041" class="usa-link" aria-describedby="jcph1480-bib-0041">41</a> and population PK/PD analyses<a href="#jcph1480-bib-0040" class="usa-link" aria-describedby="jcph1480-bib-0040">33</a>, <a href="#jcph1480-bib-0042" class="usa-link" aria-describedby="jcph1480-bib-0042">42</a> have previously been conducted on pooled data from the patisiran clinical program including single and multiple doses (0.01 to 0.5 mg/kg). The results from the present subgroup analyses are consistent with the covariate analyses of both population PK and population PK/PD models, which indicated that none of the studied intrinsic and extrinsic factors affected PK exposures of ALN‐18328 and the 2 lipid excipients (DLin‐MC3‐DMA and PEG<sub>2000</sub>‐C‐DMG), or the magnitude of serum transthyretin reduction.<a href="#jcph1480-bib-0040" class="usa-link" aria-describedby="jcph1480-bib-0040">33</a>, <a href="#jcph1480-bib-0041" class="usa-link" aria-describedby="jcph1480-bib-0041">41</a>, <a href="#jcph1480-bib-0042" class="usa-link" aria-describedby="jcph1480-bib-0042">42</a>
</p>
<p>Likewise, the frequency of AEs and SAEs did not increase with increasing PK exposure to ALN‐18328, DLin‐MC3‐DMA, or PEG<sub>2000</sub>‐C‐DMG, indicating that the incidence of these events was independent of the PK concentrations of the 3 analytes. Furthermore, the lack of relationship between PK exposure and AE or SAE incidence was consistent with the similar incidence of AEs and SAEs observed in the patisiran and placebo arms of APOLLO.<a href="#jcph1480-bib-0017" class="usa-link" aria-describedby="jcph1480-bib-0017">17</a>
</p>
<p>ADAs to patisiran were evaluated by measuring antibodies specific to PEG<sub>2000</sub>‐C‐DMG, a lipid component exposed on the surface of the lipid nanoparticle. The current results show that treatment‐emergent ADAs to PEG<sub>2000</sub>‐C‐DMG occurred at a low frequency and were transient. ADAs specific to PEG<sub>2000</sub>‐C‐DMG appeared to have no effect on PK, PD, safety, or efficacy. We noted from the literature that PEG is used in toothpaste, shampoo, moisturizers, colorants, foods, drinks, and deodorants<a href="#jcph1480-bib-0043" class="usa-link" aria-describedby="jcph1480-bib-0043">43</a>; therefore, environmental exposure to PEGylated products may be responsible for the positive ADA status of 2 patients at baseline.</p>
<p>In the APOLLO study, reductions in serum vitamin A and RBP levels paralleled the reductions in serum transthyretin levels. This observation is consistent with the role of transthyretin as a major transporter of the RBP‐retinol complex in serum.<a href="#jcph1480-bib-0004" class="usa-link" aria-describedby="jcph1480-bib-0004">4</a>, <a href="#jcph1480-bib-0005" class="usa-link" aria-describedby="jcph1480-bib-0005">5</a>, <a href="#jcph1480-bib-0044" class="usa-link" aria-describedby="jcph1480-bib-0044">44</a>, <a href="#jcph1480-bib-0045" class="usa-link" aria-describedby="jcph1480-bib-0045">45</a> The transthyretin‐RBP complex is a stable form of retinol transport, allowing its delivery to cells and preventing RBP from being filtered by the kidney.<a href="#jcph1480-bib-0005" class="usa-link" aria-describedby="jcph1480-bib-0005">5</a> Reduction in circulating transthyretin levels is expected to decrease circulating RBP and vitamin A levels. However, alternative mechanisms of vitamin A transport and tissue uptake can occur in the absence of transthyretin.<a href="#jcph1480-bib-0005" class="usa-link" aria-describedby="jcph1480-bib-0005">5</a> Although serum vitamin A levels are reduced because of reductions in serum transthyretin and RBP levels during treatment with patisiran, liver stores of vitamin A are not expected to be affected during treatment, as vitamin A uptake from the gastrointestinal tract to the liver is independent of serum transthyretin and RBP levels.<a href="#jcph1480-bib-0046" class="usa-link" aria-describedby="jcph1480-bib-0046">46</a> We noted that normal levels of hepatic retinol and retinyl ester were observed in transthyretin‐deficient mice that had no transthyretin and very low levels of plasma retinol and RBP.<a href="#jcph1480-bib-0047" class="usa-link" aria-describedby="jcph1480-bib-0047">47</a>, <a href="#jcph1480-bib-0048" class="usa-link" aria-describedby="jcph1480-bib-0048">48</a> These transthyretin‐deficient mice also had normal levels of retinol and retinyl esters in the peripheral tissues and did not develop symptoms of vitamin A deficiency.<a href="#jcph1480-bib-0047" class="usa-link" aria-describedby="jcph1480-bib-0047">47</a>, <a href="#jcph1480-bib-0048" class="usa-link" aria-describedby="jcph1480-bib-0048">48</a> Similar to the effects observed in the transthyretin‐deficient mouse model, it is expected that in patients treated with patisiran, dietary uptake and transport of vitamin A to the liver will occur by the normal mechanisms that are independent of serum transthyretin levels and that hepatic stores of retinol will be normal.<a href="#jcph1480-bib-0046" class="usa-link" aria-describedby="jcph1480-bib-0046">46</a>
</p></section><section id="jcph1480-sec-0180"><h2 class="pmc_sec_title">Conclusions</h2>
<p>Dosing of patisiran at 0.3 mg/kg every 3 weeks over 18 months in patients with hATTR amyloidosis resulted in stable steady state plasma concentrations of the siRNA (ALN‐18328) and 2 novel lipid nanoparticle constituents, with low to moderate interpatient variability. Incidence of ADAs was low and transient, with no effect on patisiran PK, transthyretin reduction, clinical efficacy, or the safety profile of patisiran. Various intrinsic factors and prior use of transthyretin tetramer stabilizers had no meaningful impact on the steady state PK exposure, serum transthyretin reduction, or clinical efficacy. Interpatient variability in ALN‐18328 PK exposure did not result in differences in serum transthyretin reduction, clinical efficacy, or safety (AEs or SAEs). Overall results indicated that the patisiran dosing regimen of 0.3 mg/kg every 3 weeks, with a maximum dose of 30 mg for patients weighing ≥100 kg, is appropriate for patients with hATTR amyloidosis.</p></section><section id="jcph1480-sec-0200"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>The data in this article were obtained from the APOLLO trial funded by Alnylam Pharmaceuticals Inc. Authors are employees of Alnylam Pharmaceuticals Inc.</p></section><section id="sec19"><h2 class="pmc_sec_title">Supporting information</h2>
<section class="sm xbox font-sm" id="jcph1480-supl-0001"><div class="caption p">
<p>
<strong>Supplementary Table S1</strong>. Steady‐State Pharmacokinetic Parameters for DLin‐MC3‐DMA and PEG<sub>2000</sub>‐C‐DMG in Patient Subgroups</p>
<p>
<strong>Supplementary Table S2</strong>. Steady‐State Pharmacokinetic Parameters and TTR Percent Reduction From Baseline in Patients by Body‐Weight Quartiles</p>
<p>
<strong>Supplementary Table S3</strong>. Summary of Treatment‐Emergent AEs by Plasma ALN‐18328, DLin‐MC3‐DMA, and PEG<sub>2000</sub>‐C‐DMG PK Exposure Quartiles</p>
<p>
<strong>Supplementary Table S4</strong>. Steady‐State Pharmacokinetic Parameters for ALN‐18328, DLin‐MC3‐DMA, and PEG<sub>2000</sub>‐C‐DMG in Patients by ADA Status</p>
<p>
<strong>Supplementary Figure S1</strong>. Effect of body weight on PK exposure (C<sub>max,ss</sub> and C<sub>p,ss(30min)</sub>) for: (A) DLin‐MC3‐DMA and (B) PEG<sub>2000</sub>‐C‐DMG. The lower and upper bounds of the rectangles represent the first and third quartiles, the horizontal line represents the median, the whiskers extend to the highest and lowest values within 1.5 × the interquartile range, and data beyond the end of the whiskers are plotted as points. Body weights associated with the 4 quartiles are: Q1, 36.2‐56.6 kg; Q2, 56.9‐65.0 kg; Q3, 66.0‐79.0 kg; and Q4, 79.5‐110 kg. ALN‐18328, patisiran drug substance (small interfering RNA); C<sub>max,ss</sub>, maximum concentration observed at end of infusion at steady state; C<sub>p(30min)</sub>, concentration observed 30 minutes postinfusion; DLin‐MC3‐DMA, lipid excipient; (6Z,9Z,28Z,31Z)‐heptatriaconta‐6,9,28,31‐tetraen‐19‐yl‐4‐(dimethylamino) butanoate; PK, pharmacokinetic; PEG<sub>2000</sub>‐C‐DMG, lipid excipient (R)‐methoxy‐PEG<sub>2000</sub>‐carbamoyl‐di‐O‐myristyl‐sn‐glyceride.</p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/6972979/bin/JCPH-60-37-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">Click here for additional data file.</a><sup> (175.5KB, docx) </sup>
</div></div></section></section><section id="jcph1480-sec-0190" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>We thank all patients and their families who were involved in the study and acknowledge the contributions of the APOLLO study investigators and study coordinators at each site. We also acknowledge the contributions of the APOLLO study team members at Alnylam Pharmaceuticals Inc.: Jared Gollob and Sunita Goyal for medical monitoring; Jim Miller, Matthew White, and Megan Melch for statistical analysis; and Yuanxin Xu for bioanalytical management. Editorial assistance was provided by Adelphi Communications (Bollington, UK) and funded by Alnylam Pharmaceuticals (Cambridge, Massachusetts).</p></section><section id="jcph1480-sec-0210" class="ack"><h2 class="pmc_sec_title">Funding</h2>
<p>This study was sponsored by Alnylam Pharmaceuticals.</p></section><section id="jcph1480-sec-0220" class="ack"><h2 class="pmc_sec_title">Data‐Sharing Statement</h2>
<p>The data that support the findings of this study are available from the corresponding author (<span>x.amy.zhang@gmail.com</span>) on reasonable request.</p></section><section id="notes1"><section id="fn-group1" class="fn-group"><div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="jcph1480-note-0001"><p>
<strong>Clinicaltrials.gov identifier</strong>: <a href="https://clinicaltrials.gov/ct2/show/NCT01960348" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01960348</a></p></div></div></section></section><section id="jcph1480-bibl-0001" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="jcph1480-bibl-0001_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="jcph1480-bib-0001">
<span class="label">1.</span><cite>
Hawkins PN, Ando Y, Dispenzeri A, Gonzalez‐Duarte A, Adams D, Suhr OB. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015;47(8):625‐638.</cite> [<a href="https://doi.org/10.3109/07853890.2015.1068949" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4720049/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26611723/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Med&amp;title=Evolving%20landscape%20in%20the%20management%20of%20transthyretin%20amyloidosis&amp;author=PN%20Hawkins&amp;author=Y%20Ando&amp;author=A%20Dispenzeri&amp;author=A%20Gonzalez%E2%80%90Duarte&amp;author=D%20Adams&amp;volume=47&amp;issue=8&amp;publication_year=2015&amp;pages=625-638&amp;pmid=26611723&amp;doi=10.3109/07853890.2015.1068949&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0002">
<span class="label">2.</span><cite>
Hanna M. Novel drugs targeting transthyretin amyloidosis. Curr Heart Fail Rep. 2014;11(1):50‐57.</cite> [<a href="https://doi.org/10.1007/s11897-013-0182-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24464360/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Heart%20Fail%20Rep&amp;title=Novel%20drugs%20targeting%20transthyretin%20amyloidosis&amp;author=M%20Hanna&amp;volume=11&amp;issue=1&amp;publication_year=2014&amp;pages=50-57&amp;pmid=24464360&amp;doi=10.1007/s11897-013-0182-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0003">
<span class="label">3.</span><cite>
Soprano DR, Herbert J, Soprano KJ, Schon EA, Goodman DS. Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat. J Biol Chem. 1985;260(21):11793‐11798.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/4044580/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Biol%20Chem&amp;title=Demonstration%20of%20transthyretin%20mRNA%20in%20the%20brain%20and%20other%20extrahepatic%20tissues%20in%20the%20rat&amp;author=DR%20Soprano&amp;author=J%20Herbert&amp;author=KJ%20Soprano&amp;author=EA%20Schon&amp;author=DS%20Goodman&amp;volume=260&amp;issue=21&amp;publication_year=1985&amp;pages=11793-11798&amp;pmid=4044580&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0004">
<span class="label">4.</span><cite>
Monaco HL, Rizzi M, Coda A. Structure of a complex of two plasma proteins: transthyretin and retinol‐binding protein. Science. 1995;268(5213):1039‐1041.</cite> [<a href="https://doi.org/10.1126/science.7754382" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7754382/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Structure%20of%20a%20complex%20of%20two%20plasma%20proteins:%20transthyretin%20and%20retinol%E2%80%90binding%20protein&amp;author=HL%20Monaco&amp;author=M%20Rizzi&amp;author=A%20Coda&amp;volume=268&amp;issue=5213&amp;publication_year=1995&amp;pages=1039-1041&amp;pmid=7754382&amp;doi=10.1126/science.7754382&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0005">
<span class="label">5.</span><cite>
Vieira M, Saraiva MJ. Transthyretin: a multifaceted protein. Biomol Concepts. 2014;5(1):45‐54.</cite> [<a href="https://doi.org/10.1515/bmc-2013-0038" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25372741/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomol%20Concepts&amp;title=Transthyretin:%20a%20multifaceted%20protein&amp;author=M%20Vieira&amp;author=MJ%20Saraiva&amp;volume=5&amp;issue=1&amp;publication_year=2014&amp;pages=45-54&amp;pmid=25372741&amp;doi=10.1515/bmc-2013-0038&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0006">
<span class="label">6.</span><cite>
Rowczenio DM, Noor I, Gillmore JD, et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat. 2014;35(9):E2403‐E2412.</cite> [<a href="https://doi.org/10.1002/humu.22619" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25044787/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hum%20Mutat&amp;title=Online%20registry%20for%20mutations%20in%20hereditary%20amyloidosis%20including%20nomenclature%20recommendations&amp;author=DM%20Rowczenio&amp;author=I%20Noor&amp;author=JD%20Gillmore&amp;volume=35&amp;issue=9&amp;publication_year=2014&amp;pages=E2403-E2412&amp;pmid=25044787&amp;doi=10.1002/humu.22619&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0007">
<span class="label">7.</span><cite>
Planté‐Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10(12):1086‐1097.</cite> [<a href="https://doi.org/10.1016/S1474-4422(11)70246-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22094129/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Neurol&amp;title=Familial%20amyloid%20polyneuropathy&amp;author=V%20Plant%C3%A9%E2%80%90Bordeneuve&amp;author=G%20Said&amp;volume=10&amp;issue=12&amp;publication_year=2011&amp;pages=1086-1097&amp;pmid=22094129&amp;doi=10.1016/S1474-4422(11)70246-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0008">
<span class="label">8.</span><cite>
Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286‐1300.</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.111.078915" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3501197/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22949539/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Transthyretin%20(TTR)%20cardiac%20amyloidosis&amp;author=FL%20Ruberg&amp;author=JL%20Berk&amp;volume=126&amp;issue=10&amp;publication_year=2012&amp;pages=1286-1300&amp;pmid=22949539&amp;doi=10.1161/CIRCULATIONAHA.111.078915&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0009">
<span class="label">9.</span><cite>
Damy T, Judge DP, Kristen AV, Berthet K, Li H, Aarts J. Cardiac findings and events observed in an open‐label clinical trial of tafamidis in patients with non‐Val30Met and non‐Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Transl Res. 2015;8(2):117‐127.</cite> [<a href="https://doi.org/10.1007/s12265-015-9613-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4382536/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25743445/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Cardiovasc%20Transl%20Res&amp;title=Cardiac%20findings%20and%20events%20observed%20in%20an%20open%E2%80%90label%20clinical%20trial%20of%20tafamidis%20in%20patients%20with%20non%E2%80%90Val30Met%20and%20non%E2%80%90Val122Ile%20hereditary%20transthyretin%20amyloidosis&amp;author=T%20Damy&amp;author=DP%20Judge&amp;author=AV%20Kristen&amp;author=K%20Berthet&amp;author=H%20Li&amp;volume=8&amp;issue=2&amp;publication_year=2015&amp;pages=117-127&amp;pmid=25743445&amp;doi=10.1007/s12265-015-9613-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0010">
<span class="label">10.</span><cite>
Conceição I, Gonzalez‐Duarte A, Obici L, et al. “Red‐flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5‐9.</cite> [<a href="https://doi.org/10.1111/jns.12153" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4788142/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26663427/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Peripher%20Nerv%20Syst&amp;title=%E2%80%9CRed%E2%80%90flag%E2%80%9D%20symptom%20clusters%20in%20transthyretin%20familial%20amyloid%20polyneuropathy&amp;author=I%20Concei%C3%A7%C3%A3o&amp;author=A%20Gonzalez%E2%80%90Duarte&amp;author=L%20Obici&amp;volume=21&amp;issue=1&amp;publication_year=2016&amp;pages=5-9&amp;pmid=26663427&amp;doi=10.1111/jns.12153&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0011">
<span class="label">11.</span><cite>
Shin SC, Robinson‐Papp J. Amyloid neuropathies. Mt Sinai J Med. 2012;79(6):733‐748.</cite> [<a href="https://doi.org/10.1002/msj.21352" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3531896/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23239211/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mt%20Sinai%20J%20Med&amp;title=Amyloid%20neuropathies&amp;author=SC%20Shin&amp;author=J%20Robinson%E2%80%90Papp&amp;volume=79&amp;issue=6&amp;publication_year=2012&amp;pages=733-748&amp;pmid=23239211&amp;doi=10.1002/msj.21352&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0012">
<span class="label">12.</span><cite>
Castaño A, Drachman BM, Judge D, Maurer MS. Natural history and therapy of TTR‐cardiac amyloidosis: emerging disease‐modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2015;20(2):163‐178.</cite> [<a href="https://doi.org/10.1007/s10741-014-9462-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4361302/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25408161/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Heart%20Fail%20Rev&amp;title=Natural%20history%20and%20therapy%20of%20TTR%E2%80%90cardiac%20amyloidosis:%20emerging%20disease%E2%80%90modifying%20therapies%20from%20organ%20transplantation%20to%20stabilizer%20and%20silencer%20drugs&amp;author=A%20Casta%C3%B1o&amp;author=BM%20Drachman&amp;author=D%20Judge&amp;author=MS%20Maurer&amp;volume=20&amp;issue=2&amp;publication_year=2015&amp;pages=163-178&amp;pmid=25408161&amp;doi=10.1007/s10741-014-9462-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0013">
<span class="label">13.</span><cite>
Swiecicki PL, Zhen DB, Mauermann ML, et al. Hereditary ATTR amyloidosis: a single‐institution experience with 266 patients. Amyloid. 2015;22(2):123‐131.</cite> [<a href="https://doi.org/10.3109/13506129.2015.1019610" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26017327/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Hereditary%20ATTR%20amyloidosis:%20a%20single%E2%80%90institution%20experience%20with%20266%20patients&amp;author=PL%20Swiecicki&amp;author=DB%20Zhen&amp;author=ML%20Mauermann&amp;volume=22&amp;issue=2&amp;publication_year=2015&amp;pages=123-131&amp;pmid=26017327&amp;doi=10.3109/13506129.2015.1019610&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0014">
<span class="label">14.</span><cite>
Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012;33(9):1120‐1127.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehr383" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21992998/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=Cardiac%20phenotype%20and%20clinical%20outcome%20of%20familial%20amyloid%20polyneuropathy%20associated%20with%20transthyretin%20alanine%2060%20variant&amp;author=PT%20Sattianayagam&amp;author=AF%20Hahn&amp;author=CJ%20Whelan&amp;volume=33&amp;issue=9&amp;publication_year=2012&amp;pages=1120-1127&amp;pmid=21992998&amp;doi=10.1093/eurheartj/ehr383&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0015">
<span class="label">15.</span><cite>
Gertz MA, Kyle RA, Thibodeau SN. Familial amyloidosis: a study of 52 North American‐born patients examined during a 30‐year period. Mayo Clin Proc. 1992;67(5):428‐440.</cite> [<a href="https://doi.org/10.1016/s0025-6196(12)60388-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1405768/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mayo%20Clin%20Proc&amp;title=Familial%20amyloidosis:%20a%20study%20of%2052%20North%20American%E2%80%90born%20patients%20examined%20during%20a%2030%E2%80%90year%20period&amp;author=MA%20Gertz&amp;author=RA%20Kyle&amp;author=SN%20Thibodeau&amp;volume=67&amp;issue=5&amp;publication_year=1992&amp;pages=428-440&amp;pmid=1405768&amp;doi=10.1016/s0025-6196(12)60388-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0016">
<span class="label">16.</span><cite>
Benson MD, Waddington‐Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22‐31.</cite> [<a href="https://doi.org/10.1056/NEJMoa1716793" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12611561/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29972757/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Inotersen%20treatment%20for%20patients%20with%20hereditary%20transthyretin%20amyloidosis&amp;author=MD%20Benson&amp;author=M%20Waddington%E2%80%90Cruz&amp;author=JL%20Berk&amp;volume=379&amp;issue=1&amp;publication_year=2018&amp;pages=22-31&amp;pmid=29972757&amp;doi=10.1056/NEJMoa1716793&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0017">
<span class="label">17.</span><cite>
Adams D, Gonzalez‐Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11‐21.</cite> [<a href="https://doi.org/10.1056/NEJMoa1716153" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29972753/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Patisiran,%20an%20RNAi%20therapeutic,%20for%20hereditary%20transthyretin%20amyloidosis&amp;author=D%20Adams&amp;author=A%20Gonzalez%E2%80%90Duarte&amp;author=WD%20O'Riordan&amp;volume=379&amp;issue=1&amp;publication_year=2018&amp;pages=11-21&amp;pmid=29972753&amp;doi=10.1056/NEJMoa1716153&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0018">
<span class="label">18.</span><cite>
Alnylam Pharmaceuticals Inc
. US prescribing information: ONPATTRO (patisiran) lipid complex injection, for intravenous use. 2018. Food and Drug Administration. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210922s000lbl.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210922s000lbl.pdf</a>. Accessed July 8, 2019.</cite>
</li>
<li id="jcph1480-bib-0019">
<span class="label">19.</span><cite>
European Medicines Agency
. Summary of product characteristics: Onpattro 2 mg/mL concentrate for solution for infusion
2018. 
<a href="https://www.ema.europa.eu/documents/product-information/onpattro-epar-product-information_en.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ema.europa.eu/documents/product-information/onpattro-epar-product-information_en.pdf</a>. Accessed July 8, 2019.</cite>
</li>
<li id="jcph1480-bib-0020">
<span class="label">20.</span><cite>
European Medicines Agency
. Summary of opinion (initial authoristation): Onpattro (patisiran) 2018. <a href="https://www.ema.europa.eu/documents/smop-initial/chmp-summary-positive-opinion-onpattro_en.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ema.europa.eu/documents/smop-initial/chmp-summary-positive-opinion-onpattro_en.pdf</a>. Accessed July 8, 2019.</cite>
</li>
<li id="jcph1480-bib-0021">
<span class="label">21.</span><cite>
Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369(9):819‐829.</cite> [<a href="https://doi.org/10.1056/NEJMoa1208760" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23984729/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Safety%20and%20efficacy%20of%20RNAi%20therapy%20for%20transthyretin%20amyloidosis&amp;author=T%20Coelho&amp;author=D%20Adams&amp;author=A%20Silva&amp;volume=369&amp;issue=9&amp;publication_year=2013&amp;pages=819-829&amp;pmid=23984729&amp;doi=10.1056/NEJMoa1208760&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0022">
<span class="label">22.</span><cite>
Mui BL, Tam YK, Jayaraman M, et al. Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles. Mol Ther Nucleic Acids. 2013;2:e139.</cite> [<a href="https://doi.org/10.1038/mtna.2013.66" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3894582/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24345865/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Ther%20Nucleic%20Acids&amp;title=Influence%20of%20polyethylene%20glycol%20lipid%20desorption%20rates%20on%20pharmacokinetics%20and%20pharmacodynamics%20of%20siRNA%20lipid%20nanoparticles&amp;author=BL%20Mui&amp;author=YK%20Tam&amp;author=M%20Jayaraman&amp;volume=2&amp;publication_year=2013&amp;pages=e139&amp;pmid=24345865&amp;doi=10.1038/mtna.2013.66&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0023">
<span class="label">23.</span><cite>
Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. Mol Ther. 2017;25(7):1467‐1475.</cite> [<a href="https://doi.org/10.1016/j.ymthe.2017.03.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5498813/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28412170/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Ther&amp;title=Lipid%20nanoparticle%20systems%20for%20enabling%20gene%20therapies&amp;author=PR%20Cullis&amp;author=MJ%20Hope&amp;volume=25&amp;issue=7&amp;publication_year=2017&amp;pages=1467-1475&amp;pmid=28412170&amp;doi=10.1016/j.ymthe.2017.03.013&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0024">
<span class="label">24.</span><cite>
Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129‐138.</cite> [<a href="https://doi.org/10.1038/nrd2742" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7097568/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19180106/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Drug%20Discov&amp;title=Knocking%20down%20barriers:%20advances%20in%20siRNA%20delivery&amp;author=KA%20Whitehead&amp;author=R%20Langer&amp;author=DG%20Anderson&amp;volume=8&amp;issue=2&amp;publication_year=2009&amp;pages=129-138&amp;pmid=19180106&amp;doi=10.1038/nrd2742&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0025">
<span class="label">25.</span><cite>
Leung AK, Hafez IM, Baoukina S, et al. Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron‐dense nanostructured Core. J Phys Chem C Nanomater Interfaces. 2012;116(34):18440‐18450.</cite> [<a href="https://doi.org/10.1021/jp303267y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3434764/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22962627/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Phys%20Chem%20C%20Nanomater%20Interfaces&amp;title=Lipid%20nanoparticles%20containing%20siRNA%20synthesized%20by%20microfluidic%20mixing%20exhibit%20an%20electron%E2%80%90dense%20nanostructured%20Core&amp;author=AK%20Leung&amp;author=IM%20Hafez&amp;author=S%20Baoukina&amp;volume=116&amp;issue=34&amp;publication_year=2012&amp;pages=18440-18450&amp;pmid=22962627&amp;doi=10.1021/jp303267y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0026">
<span class="label">26.</span><cite>
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double‐stranded RNA in <em>Caenorhabditis elegans</em>
. Nature. 1998;391(6669):806‐811.</cite> [<a href="https://doi.org/10.1038/35888" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9486653/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Potent%20and%20specific%20genetic%20interference%20by%20double%E2%80%90stranded%20RNA%20in%20Caenorhabditis%20elegans&amp;author=A%20Fire&amp;author=S%20Xu&amp;author=MK%20Montgomery&amp;author=SA%20Kostas&amp;author=SE%20Driver&amp;volume=391&amp;issue=6669&amp;publication_year=1998&amp;pages=806-811&amp;pmid=9486653&amp;doi=10.1038/35888&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0027">
<span class="label">27.</span><cite>
Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21‐nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411(6836):494‐498.</cite> [<a href="https://doi.org/10.1038/35078107" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11373684/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Duplexes%20of%2021%E2%80%90nucleotide%20RNAs%20mediate%20RNA%20interference%20in%20cultured%20mammalian%20cells&amp;author=SM%20Elbashir&amp;author=J%20Harborth&amp;author=W%20Lendeckel&amp;author=A%20Yalcin&amp;author=K%20Weber&amp;volume=411&amp;issue=6836&amp;publication_year=2001&amp;pages=494-498&amp;pmid=11373684&amp;doi=10.1038/35078107&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0028">
<span class="label">28.</span><cite>
European Medicines Agency
. Assessment report: onpattro (patisiran) 2018. <a href="https://www.ema.europa.eu/documents/assessment-report/onpattro-epar-public-assessment-report_.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ema.europa.eu/documents/assessment-report/onpattro-epar-public-assessment-report_.pdf</a>. Accessed July 8, 2019.</cite>
</li>
<li id="jcph1480-bib-0029">
<span class="label">29.</span><cite>
Suhr OB, Coelho T, Buades J, et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi‐dose study. Orphanet J Rare Dis. 2015;10:109.</cite> [<a href="https://doi.org/10.1186/s13023-015-0326-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4559363/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26338094/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Orphanet%20J%20Rare%20Dis&amp;title=Efficacy%20and%20safety%20of%20patisiran%20for%20familial%20amyloidotic%20polyneuropathy:%20a%20phase%20II%20multi%E2%80%90dose%20study&amp;author=OB%20Suhr&amp;author=T%20Coelho&amp;author=J%20Buades&amp;volume=10&amp;publication_year=2015&amp;pages=109&amp;pmid=26338094&amp;doi=10.1186/s13023-015-0326-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0030">
<span class="label">30.</span><cite>
Adams D, Suhr OB, Dyck PJ, et al. Trial design and rationale for APOLLO, a phase 3, placebo‐controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurol. 2017;17(1):181.</cite> [<a href="https://doi.org/10.1186/s12883-017-0948-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5594468/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28893208/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Neurol&amp;title=Trial%20design%20and%20rationale%20for%20APOLLO,%20a%20phase%203,%20placebo%E2%80%90controlled%20study%20of%20patisiran%20in%20patients%20with%20hereditary%20ATTR%20amyloidosis%20with%20polyneuropathy&amp;author=D%20Adams&amp;author=OB%20Suhr&amp;author=PJ%20Dyck&amp;volume=17&amp;issue=1&amp;publication_year=2017&amp;pages=181&amp;pmid=28893208&amp;doi=10.1186/s12883-017-0948-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0031">
<span class="label">31.</span><cite>
Suanprasert N, Berk JL, Benson MD, et al. Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials. J Neurol Sci. 2014;344(1‐2):121‐128.</cite> [<a href="https://doi.org/10.1016/j.jns.2014.06.041" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25012480/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurol%20Sci&amp;title=Retrospective%20study%20of%20a%20TTR%20FAP%20cohort%20to%20modify%20NIS+7%20for%20therapeutic%20trials&amp;author=N%20Suanprasert&amp;author=JL%20Berk&amp;author=MD%20Benson&amp;volume=344&amp;issue=1%E2%80%902&amp;publication_year=2014&amp;pages=121-128&amp;pmid=25012480&amp;doi=10.1016/j.jns.2014.06.041&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0032">
<span class="label">32.</span><cite>
Zhang X, Goel V, Robbie G. Pharmacokinetics of patisiran in patients with hereditary transthyretin‐mediated amyloidosis. J Neuromuscul Dis. 2018;5(s1):S280‐S282 Abstract 568.</cite> [<a href="https://doi.org/10.1002/jcph.1553" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7187331/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31777097/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neuromuscul%20Dis&amp;title=Pharmacokinetics%20of%20patisiran%20in%20patients%20with%20hereditary%20transthyretin%E2%80%90mediated%20amyloidosis&amp;author=X%20Zhang&amp;author=V%20Goel&amp;author=G%20Robbie&amp;volume=5&amp;issue=s1&amp;publication_year=2018&amp;pages=S280-S282&amp;pmid=31777097&amp;doi=10.1002/jcph.1553&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0040">
<span class="label">33.</span><cite>
Center for Drug Evaluation and Research (CDER) Food and Drug Administration
. Multi‐discipline review: patisiran. Population PK and/or PD analyses
2018.  NDA210992. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210922Orig1s000MultiR.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210922Orig1s000MultiR.pdf</a>. Accessed July 8, 2019.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Multi%E2%80%90discipline%20review:%20patisiran.%20Population%20PK%20and/or%20PD%20analyses&amp;publication_year=2018&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0033">
<span class="label">34.</span><cite>
Food and Drug Administration
. Guidance for industry: pharmacokinetics in patients with impaired renal function — study design, data analysis, and impact on dosing and labeling: Center for Drug Evaluation and Research (CDER); 2010. 
<a href="https://www.fda.gov/downloads/drugs/guidances/ucm204959.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.fda.gov/downloads/drugs/guidances/ucm204959.pdf</a>. Accessed July 8, 2019.</cite>
</li>
<li id="jcph1480-bib-0034">
<span class="label">35.</span><cite>
Patel H, Egorin MJ, Remick SC, et al. Comparison of Child‐Pugh (CP) criteria and NCI organ dysfunction working group (NCI‐ODWG) criteria for hepatic dysfunction (HD): Implications for chemotherapy dosing. J Clin Oncol. 2004;22(suppl 14):6051.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Comparison%20of%20Child%E2%80%90Pugh%20(CP)%20criteria%20and%20NCI%20organ%20dysfunction%20working%20group%20(NCI%E2%80%90ODWG)%20criteria%20for%20hepatic%20dysfunction%20(HD):%20Implications%20for%20chemotherapy%20dosing&amp;author=H%20Patel&amp;author=MJ%20Egorin&amp;author=SC%20Remick&amp;volume=22&amp;issue=suppl%2014&amp;publication_year=2004&amp;pages=6051&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0035">
<span class="label">36.</span><cite>
du Prel J‐B, Rohrig B, Hommel G, Blettner M. Choosing statistical tests. Dtsch Arztebl Int. 2010;107(19):343‐348.</cite> [<a href="https://doi.org/10.3238/arztebl.2010.0343" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2881615/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20532129/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Dtsch%20Arztebl%20Int&amp;title=Choosing%20statistical%20tests&amp;author=J%E2%80%90B%20du%20Prel&amp;author=B%20Rohrig&amp;author=G%20Hommel&amp;author=M%20Blettner&amp;volume=107&amp;issue=19&amp;publication_year=2010&amp;pages=343-348&amp;pmid=20532129&amp;doi=10.3238/arztebl.2010.0343&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0036">
<span class="label">37.</span><cite>
Benjamini Y, Yekutielli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat. 2001;29(4):1165‐1188.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Stat&amp;title=The%20control%20of%20the%20false%20discovery%20rate%20in%20multiple%20testing%20under%20dependency&amp;author=Y%20Benjamini&amp;author=D%20Yekutielli&amp;volume=29&amp;issue=4&amp;publication_year=2001&amp;pages=1165-1188&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0037">
<span class="label">38.</span><cite>
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Society Series B. 1995;57(1):289‐300.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Royal%20Stat%20Society%20Series%20B&amp;title=Controlling%20the%20false%20discovery%20rate:%20a%20practical%20and%20powerful%20approach%20to%20multiple%20testing&amp;author=Y%20Benjamini&amp;author=Y%20Hochberg&amp;volume=57&amp;issue=1&amp;publication_year=1995&amp;pages=289-300&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0038">
<span class="label">39.</span><cite>
R Core Team
. R: a language and environment for statistical computing. R Foundation for Statistical Computing. <a href="https://www.r-project.org/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.r-project.org/</a>. Accessed July 8, 2019.</cite>
</li>
<li id="jcph1480-bib-0039">
<span class="label">40.</span><cite>
Judge DP, Falk RH, Maurer MS, et al. Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy [published online ahead of print 2019]. J Am Coll Cardiol. 10.1016/j.jacc.2019.03.012. Accessed July 8, 2019.</cite> [<a href="https://doi.org/10.1016/j.jacc.2019.03.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30885685/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Transthyretin%20stabilization%20by%20AG10%20in%20symptomatic%20transthyretin%20amyloid%20cardiomyopathy&amp;author=DP%20Judge&amp;author=RH%20Falk&amp;author=MS%20Maurer&amp;pmid=30885685&amp;doi=10.1016/j.jacc.2019.03.012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0041">
<span class="label">41.</span><cite>
Goel V, Jomphe C, Gosselin N, et al. Population pharmacokinetics (PK) of investigational patisiran in healthy volunteers and in patients. Presented at: 15th International Congress on Neuromuscular Diseases (ICNMD); July 6‐10, 2018; Vienna, Austria.</cite>
</li>
<li id="jcph1480-bib-0042">
<span class="label">42.</span><cite>
Goel V, Gosselin N, Jomphe C, et al. Popluation pharmacokinetic (PK)/pharmacodynamic (PD) model of serum transthyretin (TTR) following patisiran‐LNP administration in healthy volunteers and patients with hereditary TTR mediated (hATTR) amyloidosis with polyneuropathy. Presented at: European Academy of Neurology (EAN); June 16‐19, 2018; Lisbon, Portugal.</cite>
</li>
<li id="jcph1480-bib-0043">
<span class="label">43.</span><cite>
Webster R, Didier E, Harris P, et al. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos. 2007;35(1):9‐16.</cite> [<a href="https://doi.org/10.1124/dmd.106.012419" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17020954/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drug%20Metab%20Dispos&amp;title=PEGylated%20proteins:%20evaluation%20of%20their%20safety%20in%20the%20absence%20of%20definitive%20metabolism%20studies&amp;author=R%20Webster&amp;author=E%20Didier&amp;author=P%20Harris&amp;volume=35&amp;issue=1&amp;publication_year=2007&amp;pages=9-16&amp;pmid=17020954&amp;doi=10.1124/dmd.106.012419&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0044">
<span class="label">44.</span><cite>
Goodman DS. Vitamin A and retinoids in health and disease. N Engl J Med. 1984;310(16):1023‐1031.</cite> [<a href="https://doi.org/10.1056/NEJM198404193101605" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/6369133/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Vitamin%20A%20and%20retinoids%20in%20health%20and%20disease&amp;author=DS%20Goodman&amp;volume=310&amp;issue=16&amp;publication_year=1984&amp;pages=1023-1031&amp;pmid=6369133&amp;doi=10.1056/NEJM198404193101605&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0045">
<span class="label">45.</span><cite>
Noy N, Slosberg E, Scarlata S. Interactions of retinol with binding proteins: studies with retinol‐binding protein and with transthyretin. Biochemistry. 1992;31(45):11118‐11124.</cite> [<a href="https://doi.org/10.1021/bi00160a023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1445851/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochemistry&amp;title=Interactions%20of%20retinol%20with%20binding%20proteins:%20studies%20with%20retinol%E2%80%90binding%20protein%20and%20with%20transthyretin&amp;author=N%20Noy&amp;author=E%20Slosberg&amp;author=S%20Scarlata&amp;volume=31&amp;issue=45&amp;publication_year=1992&amp;pages=11118-11124&amp;pmid=1445851&amp;doi=10.1021/bi00160a023&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0046">
<span class="label">46.</span><cite>
European Food Safety Authority (EFSA)
. Scientific opinion on dietary reference values for vitamin A: EFSA panel on dietetic products, nutrition, and allergies (NDA). EFSA J. 2015;13(3):4028.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=EFSA%20J&amp;title=Scientific%20opinion%20on%20dietary%20reference%20values%20for%20vitamin%20A:%20EFSA%20panel%20on%20dietetic%20products,%20nutrition,%20and%20allergies%20(NDA)&amp;volume=13&amp;issue=3&amp;publication_year=2015&amp;pages=4028&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0047">
<span class="label">47.</span><cite>
Episkopou V, Maeda S, Nishiguchi S, et al. Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc Natl Acad Sci U S A. 1993;90(6):2375‐2379.</cite> [<a href="https://doi.org/10.1073/pnas.90.6.2375" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC46089/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8384721/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;title=Disruption%20of%20the%20transthyretin%20gene%20results%20in%20mice%20with%20depressed%20levels%20of%20plasma%20retinol%20and%20thyroid%20hormone&amp;author=V%20Episkopou&amp;author=S%20Maeda&amp;author=S%20Nishiguchi&amp;volume=90&amp;issue=6&amp;publication_year=1993&amp;pages=2375-2379&amp;pmid=8384721&amp;doi=10.1073/pnas.90.6.2375&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="jcph1480-bib-0048">
<span class="label">48.</span><cite>
Wei S, Episkopou V, Piantedosi R, et al. Studies on the metabolism of retinol and retinol‐binding protein in transthyretin‐deficient mice produced by homologous recombination. J Biol Chem. 1995;270(2):866‐870.</cite> [<a href="https://doi.org/10.1074/jbc.270.2.866" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7822324/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Biol%20Chem&amp;title=Studies%20on%20the%20metabolism%20of%20retinol%20and%20retinol%E2%80%90binding%20protein%20in%20transthyretin%E2%80%90deficient%20mice%20produced%20by%20homologous%20recombination&amp;author=S%20Wei&amp;author=V%20Episkopou&amp;author=R%20Piantedosi&amp;volume=270&amp;issue=2&amp;publication_year=1995&amp;pages=866-870&amp;pmid=7822324&amp;doi=10.1074/jbc.270.2.866&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p">
<p>
<strong>Supplementary Table S1</strong>. Steady‐State Pharmacokinetic Parameters for DLin‐MC3‐DMA and PEG<sub>2000</sub>‐C‐DMG in Patient Subgroups</p>
<p>
<strong>Supplementary Table S2</strong>. Steady‐State Pharmacokinetic Parameters and TTR Percent Reduction From Baseline in Patients by Body‐Weight Quartiles</p>
<p>
<strong>Supplementary Table S3</strong>. Summary of Treatment‐Emergent AEs by Plasma ALN‐18328, DLin‐MC3‐DMA, and PEG<sub>2000</sub>‐C‐DMG PK Exposure Quartiles</p>
<p>
<strong>Supplementary Table S4</strong>. Steady‐State Pharmacokinetic Parameters for ALN‐18328, DLin‐MC3‐DMA, and PEG<sub>2000</sub>‐C‐DMG in Patients by ADA Status</p>
<p>
<strong>Supplementary Figure S1</strong>. Effect of body weight on PK exposure (C<sub>max,ss</sub> and C<sub>p,ss(30min)</sub>) for: (A) DLin‐MC3‐DMA and (B) PEG<sub>2000</sub>‐C‐DMG. The lower and upper bounds of the rectangles represent the first and third quartiles, the horizontal line represents the median, the whiskers extend to the highest and lowest values within 1.5 × the interquartile range, and data beyond the end of the whiskers are plotted as points. Body weights associated with the 4 quartiles are: Q1, 36.2‐56.6 kg; Q2, 56.9‐65.0 kg; Q3, 66.0‐79.0 kg; and Q4, 79.5‐110 kg. ALN‐18328, patisiran drug substance (small interfering RNA); C<sub>max,ss</sub>, maximum concentration observed at end of infusion at steady state; C<sub>p(30min)</sub>, concentration observed 30 minutes postinfusion; DLin‐MC3‐DMA, lipid excipient; (6Z,9Z,28Z,31Z)‐heptatriaconta‐6,9,28,31‐tetraen‐19‐yl‐4‐(dimethylamino) butanoate; PK, pharmacokinetic; PEG<sub>2000</sub>‐C‐DMG, lipid excipient (R)‐methoxy‐PEG<sub>2000</sub>‐carbamoyl‐di‐O‐myristyl‐sn‐glyceride.</p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/6972979/bin/JCPH-60-37-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">Click here for additional data file.</a><sup> (175.5KB, docx) </sup>
</div></div></section></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Journal of Clinical Pharmacology are provided here courtesy of <strong>Wiley</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1002/jcph.1480"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/JCPH-60-37.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1008.5 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/6972979/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/6972979/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC6972979%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC6972979/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC6972979/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC6972979/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/31322739/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC6972979/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/31322739/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC6972979/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/6972979/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="GP6X061O7PdQHDsyKvrYBtEktJEfdcxYHyTEtRp04bsm16LTYJwEp76UexUPQMeC">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
